###begin article-title 0
###xml 14 15 14 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
Purinergic P2X7 receptors regulate secretion of interleukin-1 receptor antagonist and beta cell function and survival
###end article-title 0
###begin title 1
Aims/hypothesis
###end title 1
###begin p 2
###xml 396 397 396 397 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
In obesity, beta cells activate compensatory mechanisms to adapt to the higher insulin demand. Interleukin-1 receptor antagonist (IL-1Ra) prevents obesity-induced hyperglycaemia and is a potent target for the treatment of diabetes, but the mechanisms of its secretion and regulation in obesity are unknown. In the present study, we hypothesise the regulation of IL-1Ra secretion by purinergic P2X7 receptors in islets.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 32 33 32 33 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 248 252 245 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2x7</italic>
###xml 268 273 265 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2Rx7</italic>
###xml 99 107 <span type="species:ncbi:9606">patients</span>
###xml 284 288 <span type="species:ncbi:10090">mice</span>
Production and regulation of P2X7 were studied in pancreatic sections from lean and obese diabetic patients, non-diabetic controls and in isolated islets. IL-1Ra, IL-1beta and insulin secretion, glucose tolerance and beta cell mass were studied in P2x7 (also known as P2Rx7)-knockout mice.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 3 4 3 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 189 190 189 190 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 258 259 258 259 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 305 309 305 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2x7</italic>
###xml 49 57 <span type="species:ncbi:9606">patients</span>
###xml 80 88 <span type="species:ncbi:9606">patients</span>
###xml 215 220 <span type="species:ncbi:9606">human</span>
###xml 319 323 <span type="species:ncbi:10090">mice</span>
P2X7 levels were elevated in beta cells of obese patients, but downregulated in patients with type 2 diabetes mellitus. Elevated glucose and non-esterified fatty acids rapidly activated P2X7 and IL-1Ra secretion in human islets, and this was inhibited by P2X7 blockade. In line with our results in vitro, P2x7-knockout mice had a lower capacity to secrete IL-1Ra. They exhibited severe and rapid hyperglycaemia, glucose intolerance and impaired beta cell function in response to a high-fat/high-sucrose diet, were unable to compensate by increasing their beta cell mass in response to the diet and showed increased beta cell apoptosis.
###end p 6
###begin title 7
Conclusions/interpretation
###end title 7
###begin p 8
###xml 42 43 42 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 139 140 139 140 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
Our study shows a tight correlation of P2X7 activation, IL-1Ra secretion and regulation of beta cell mass and function. The increase in P2X7 production is one mechanism that may explain how beta cells compensate by adapting to the higher insulin demand. Disturbances within that system may result in the progression of diabetes.
###end p 8
###begin title 9
Electronic supplementary material
###end title 9
###begin p 10
The online version of this article (doi:10.1007/s00125-009-1349-0) contains supplementary material, which is available to authorised users.
###end p 10
###begin title 11
Keywords
###end title 11
###begin title 12
Introduction
###end title 12
###begin p 13
###xml 254 255 254 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 386 387 386 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 783 784 783 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 955 956 949 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 1088 1089 1071 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 1090 1091 1073 1074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 1142 1143 1125 1126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 269 275 <span type="species:ncbi:9606">people</span>
An alarming increase in obesity and type 2 diabetes mellitus has been recorded among the global population. The rise in type 2 diabetes is tightly connected with a dramatic increase in obesity, a major risk factor for the development of type 2 diabetes [1]. Most obese people have become insulin resistant but compensate for the enhanced insulin demand by increasing insulin secretion [2]. In order to explore how beta cells increase mass under physiological conditions, it is important to stimulate beta cell expansion in vivo and in vitro. The pathology of type 2 diabetes comprises initial hyperinsulinaemia with, thereafter, a continuous decline in beta cell function in association with a progressive decrease in beta cell mass due to an increasing rate of beta cell apoptosis [3]. A previously described mechanism for glucose-induced beta cell apoptosis involves the production and secretion of interleukin-1beta (IL-1beta) by the beta cell itself [4], which is blocked by an anti-inflammatory cytokine and naturally occurring antagonist of interleukin-1alpha (IL-1alpha) and beta [5-7], the interleukin-1 receptor antagonist (IL-1Ra) [8]. Similarly to IL-1beta, IL-1Ra binds to type 1 and 2 IL-1 receptors (IL-1R1, IL-1R2), but lacks a second binding domain. IL-1Ra does not recruit the IL-1 receptor accessory protein, the second component of the receptor complex, and blocks IL-1R1 signalling. Endogenous production and secretion of IL-1Ra has been shown to limit inflammation and tissue damage.
###end p 13
###begin p 14
###xml 69 70 66 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 72 74 69 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 131 133 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 160 162 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 296 298 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 265 273 <span type="species:ncbi:9606">patients</span>
Exogenous IL-1Ra protects against IL-1beta-induced beta cell damage [9, 10], counteracts low-dose-streptozotocin-induced diabetes [11] and autoimmune diabetes [12]. Results from a clinical study show that IL-1Ra improves glycaemic control and beta cell function in patients with type 2 diabetes [13].
###end p 14
###begin p 15
###xml 226 227 223 224 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 241 242 238 239 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 245 247 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 254 255 251 252 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 481 483 478 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 660 661 654 655 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 681 683 675 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 685 687 679 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 817 818 811 812 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 894 896 888 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
The secretory mechanisms and those regulating changes of IL-1Ra are unknown. An increasing body of evidence suggests that IL-1beta, as well as intracellular IL-1Ra, is secreted by a leaderless pathway via activation of the P2X7 receptor (P2X7; [14]). P2X7, a member of the purinergic receptor family, is a G-protein-coupled ionotropic receptor for extracellular ATP that forms a pore in response to ligand stimulation, regulating cell permeability, cytokine release and apoptosis [15]. The cytokine IL-1beta, which lacks a leader signal sequence, does not follow the classic endoplasmic-reticulum-to-Golgi pathway of secretion. Its secretion is governed by P2X7-mediated pathways [16, 17]. This raises a question about the mechanisms of its release; it has been demonstrated that it is secreted upon activation of P2X7 receptors, leading to shedding of microvesicles that contain the cytokine [18].
###end p 15
###begin p 16
###xml 33 34 33 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 155 156 155 156 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 267 268 267 268 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 391 392 391 392 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 520 521 520 521 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
The pore-forming ATP receptor P2X7 is also responsible for IL-1Ra release in endothelial cells and macrophages [14]. Consequently, we hypothesised that P2X7 could be involved in IL-1Ra release in beta cells. The work presented here evaluates an important role for P2X7 in beta cells, not only for cytokine release but also for insulin release and apoptosis. We have found upregulation of P2X7 in islets from obese individuals, while receptors were almost undetectable in type 2 diabetes. We then investigated whether P2X7 is involved in the compensatory mechanisms of the beta cells in response to an increased insulin demand in insulin resistance.
###end p 16
###begin title 17
Methods
###end title 17
###begin p 18
###xml 0 7 0 7 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Animals</bold>
###xml 7 11 7 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2x7</italic>
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2rx7</italic>
###xml 58 63 58 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2rx7</italic>
###xml 63 69 63 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tm1Gab</italic>
###xml 63 69 63 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>tm1Gab</italic></sup>
###xml 76 77 76 77 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 371 372 371 372 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 582 583 582 583 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 769 771 769 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 812 845 812 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="MOESM1">Electronic supplementary material</xref>
###xml 43 47 <span type="species:ncbi:10090">mice</span>
###xml 105 109 <span type="species:ncbi:10090">mice</span>
###xml 159 163 <span type="species:ncbi:10090">mice</span>
AnimalsP2x7 (also known as P2rx7)-knockout mice (B6.129P2-P2rx7tm1Gab/J; P2X7-KO) backcrossed to C57BL/6 mice for ten generations and C57BL/6 J wild-type (WT) mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA) at 4 weeks of age. Beginning at 5 weeks of age and continuing for 16 weeks, knockout as well as wild-type animals were fed a normal diet (ND; P2X7-KO-ND and WT-ND, respectively; normal diet was Harlan Teklad Rodent Diet 8604, containing 12.2, 57.6 and 30.2% energy from fat, carbohydrate and protein, respectively) or a high-fat/high-sucrose diet (HFD; P2X7-KO-HFD and WT-HFD; high-fat/high-sucrose diet was Surwit diet, Research Diets, New Brunswick, NJ, USA containing 58, 26 and 16% energy from fat, carbohydrate and protein, respectively [19]). Further details are described in the Electronic supplementary material (ESM).
###end p 18
###begin p 19
###xml 0 51 0 51 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Intraperitoneal glucose and insulin tolerance tests</bold>
###xml 463 464 462 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 331 336 <span type="species:ncbi:9606">human</span>
Intraperitoneal glucose and insulin tolerance tests At the beginning of the experiment and after 4, 8, 12 and 16 weeks of diet, all animals underwent in vivo studies. For intraperitoneal glucose tolerance tests (IPGTTs), glucose at a dose of 1 g/kg body weight and for intraperitoneal insulin tolerance tests (IPITTs), recombinant human insulin (Novolin; Novo Nordisk, Bagsvaerd, Denmark) at a dose of 0.5 U/kg was injected intraperitoneally as described before [9].
###end p 19
###begin p 20
###xml 0 27 0 27 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Islet isolation and culture</bold>
###xml 257 259 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 358 360 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 517 519 511 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 73 77 <span type="species:ncbi:10090">mice</span>
###xml 262 267 <span type="species:ncbi:9606">Human</span>
###xml 363 368 <span type="species:ncbi:10090">Mouse</span>
###xml 437 442 <span type="species:ncbi:9606">human</span>
Islet isolation and culture After 12 and 16 weeks of diet and treatment, mice were killed, blood was taken by cardiac puncture and serum stored at -80degreesC until further analysis. Thereafter, islets from all groups were isolated as described previously [20]. Human islets were isolated from pancreases of six healthy organ donors as described previously [21]. Mouse islets were cultured in RPMI-1640 medium (11.1 mmol/l glucose), and human islets in CMRL-1066 medium (5.5 mmol/l glucose), as described previously [22].
###end p 20
###begin p 21
###xml 26 27 26 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 0 43 0 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Functional analysis of P2X<sub>7</sub> in human islets</bold>
###xml 301 303 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 343 346 342 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="MOESM1">ESM</xref>
###xml 31 36 <span type="species:ncbi:9606">human</span>
###xml 61 66 <span type="species:ncbi:9606">human</span>
Functional analysis of P2X7 in human islets Freshly isolated human islets were grown on dishes coated with extracellular matrix until a monolayer formed. Cells were loaded with 10 mumol/l YO-PRO-1 (0.375 kDa; Molecular Probes/Invitrogen, Carlsbad, CA, USA) in PBS after a protocol by Narcisse et al. [15]. Further details are described in the ESM.
###end p 21
###begin p 22
###xml 0 36 0 36 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Glucose-stimulated insulin secretion</bold>
###xml 201 202 201 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 347 352 <span type="species:ncbi:10090">mouse</span>
###xml 356 361 <span type="species:ncbi:9606">human</span>
Glucose-stimulated insulin secretion Islets used to perform glucose-stimulated insulin secretion (GSIS) experiments were kept in culture medium for 24 h and GSIS was performed as described previously [9]. Islets were extracted with 0.18 mol/l HCl in 70% (vol./vol.) ethanol for determination of insulin content. Islet insulin was determined using mouse or human insulin ELISA (ALPCO, Salem, NH, USA).
###end p 22
###begin p 23
###xml 0 28 0 25 <bold xmlns:xlink="http://www.w3.org/1999/xlink">IL-1Ra and IL-1&#946; analysis</bold>
###xml 243 246 237 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="MOESM1">ESM</xref>
###xml 117 122 <span type="species:ncbi:10090">mouse</span>
###xml 160 165 <span type="species:ncbi:10090">mouse</span>
IL-1Ra and IL-1beta analysis Serum obtained from retro-orbital bleedings and cell culture supernatant fractions from mouse isolated islets were evaluated using mouse IL-1Ra or IL-1beta Quantikine ELISA (R&D Systems, Minneapolis, MN, USA) (see ESM).
###end p 23
###begin p 24
###xml 0 41 0 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Beta cell mass and histochemical analyses</bold>
###xml 372 373 366 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 379 380 373 374 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 410 413 404 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="MOESM1">ESM</xref>
###xml 601 602 595 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="MOESM2">1</xref>
###xml 416 421 <span type="species:ncbi:9606">Human</span>
###xml 503 509 <span type="species:ncbi:9606">people</span>
Beta cell mass and histochemical analyses After 12 weeks of diet and treatment, pancreases were weighed and fixed overnight in 4% (vol./vol.) paraformaldehyde at 4degreesC under continuous shaking followed by paraffin embedding, orienting pancreases such that sections were cut along the head-tail axis. Beta cell mass and apoptosis were analysed as described previously [8] (P2X7 staining is described in the ESM). Human pancreatic tissue was obtained at autopsy from non-diabetic individuals and from people with type 2 diabetes (all with documented fasting plasma glucose >8.048 mmol/l). ESM Table 1 summarises age, BMI, sex, glucose levels and diagnosis.
###end p 24
###begin p 25
###xml 0 31 0 31 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RNA extraction and PCR analysis</bold>
###xml 128 129 128 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 150 154 150 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2X7</italic>
RNA extraction and PCR analysis The total RNA of isolated islets was extracted after overnight culture as described previously [8]. The primers were: P2X7 5'AGATCGTGGAGAATGGAGTG3/5'TCTCGTGGTGTAGTTGTGG3'; tubulin 5'TCCACGTTGGCCAGGCTGGTGTCCAG3'/5'CTGTGATGAGCTGCTCAGGGTGG3'.
###end p 25
###begin p 26
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Western blot analysis</bold>
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 222 223 222 223 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 207 213 <span type="species:ncbi:9986">rabbit</span>
###xml 258 264 <span type="species:ncbi:9986">rabbit</span>
###xml 388 399 <span type="species:ncbi:3704">horseradish</span>
###xml 423 429 <span type="species:ncbi:9986">rabbit</span>
Western blot analysis Islet lysates were prepared from 100 islets per treatment condition as described previously [23]. PVDF filters (Amersham Biosciences/GE Healthcare, Uppsala, Sweden) were incubated with rabbit anti-P2X7 (Almone Labs, Jerusalem, Israel), rabbit-anti-IL-1Ra (R&D Systems) and anti-actin (#4967; Cell Signaling Technology, Beverly, MA, USA), followed by incubation with horseradish-peroxidase-linked anti-rabbit IgG.
###end p 26
###begin p 27
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Statistical analysis</bold>
###xml 232 233 230 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
Statistical analysis Samples were evaluated in a randomised manner by two investigators (R. Glas and K. Maedler) who were blinded to the treatment conditions. Data are presented as means +/- SE and were analysed by paired Student's t test or by analysis of variance with a Bonferroni correction for multiple group comparisons.
###end p 27
###begin title 28
Results
###end title 28
###begin p 29
###xml 3 4 3 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 0 80 0 80 <bold xmlns:xlink="http://www.w3.org/1999/xlink">P2X<sub>7</sub> is produced in beta cells, upregulated in obesity and decreased in diabetes</bold>
###xml 111 112 111 112 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 196 197 196 197 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 242 243 242 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 273 274 273 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 333 334 333 334 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 341 342 341 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 379 380 379 380 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 437 438 437 438 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 490 491 490 491 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 663 664 663 664 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 683 684 683 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 716 717 716 717 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 970 971 970 971 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1007 1008 1007 1008 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1065 1071 1065 1071 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 1074 1075 1074 1075 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1153 1154 1153 1154 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1190 1191 1190 1191 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1360 1361 1360 1361 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1388 1389 1388 1389 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1407 1408 1407 1408 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1441 1442 1441 1442 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1526 1527 1526 1527 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1745 1746 1745 1746 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 2008 2009 2008 2009 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1071 2144 1071 2144 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30">P2X<sub>7</sub> is produced in beta cells, upregulated in obesity and decreased in diabetes. <bold>a</bold> Agarose gel of the PCR products P2X<sub>7</sub> and tubulin obtained using cDNA from isolated human islets that was pretested for insulin production; mRNA served as a negative control (&#8722;). RT, reverse transcriptase. <bold>b</bold> Western blot to detect P2X<sub>7</sub> in human islets. <bold>c</bold> Immunofluorescence to detect P2X<sub>7</sub> and insulin in human pancreatic islets cultured for 24&#160;h at 5.5&#160;mmol/l glucose. P2X<sub>7</sub> is shown in red and insulin, a marker for beta cells, in green. Co-localisation (&#8216;Merge&#8217;) is visible as yellow. The results are representative of at least three independent experiments using islets from three donors. <bold>d</bold> Paraffin-embedded human pancreatic sections from a lean non-diabetic control (first row), an obese control (second row), a lean patient with type 2 diabetes (third row) and an obese patient with type 2 diabetes (fourth row) were analysed for the presence of P2X<sub>7</sub> (shown in red) and insulin (green). Co-localisation is visible in yellow. The results represent five independent cases from each group</p>
###xml 1071 2144 1071 2144 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="30">P2X<sub>7</sub> is produced in beta cells, upregulated in obesity and decreased in diabetes. <bold>a</bold> Agarose gel of the PCR products P2X<sub>7</sub> and tubulin obtained using cDNA from isolated human islets that was pretested for insulin production; mRNA served as a negative control (&#8722;). RT, reverse transcriptase. <bold>b</bold> Western blot to detect P2X<sub>7</sub> in human islets. <bold>c</bold> Immunofluorescence to detect P2X<sub>7</sub> and insulin in human pancreatic islets cultured for 24&#160;h at 5.5&#160;mmol/l glucose. P2X<sub>7</sub> is shown in red and insulin, a marker for beta cells, in green. Co-localisation (&#8216;Merge&#8217;) is visible as yellow. The results are representative of at least three independent experiments using islets from three donors. <bold>d</bold> Paraffin-embedded human pancreatic sections from a lean non-diabetic control (first row), an obese control (second row), a lean patient with type 2 diabetes (third row) and an obese patient with type 2 diabetes (fourth row) were analysed for the presence of P2X<sub>7</sub> (shown in red) and insulin (green). Co-localisation is visible in yellow. The results represent five independent cases from each group</p></caption>
###xml 2144 2144 2144 2144 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="125_2009_1349_Fig1_HTML" id="MO1"/>
###xml 1065 2144 1065 2144 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="30">P2X<sub>7</sub> is produced in beta cells, upregulated in obesity and decreased in diabetes. <bold>a</bold> Agarose gel of the PCR products P2X<sub>7</sub> and tubulin obtained using cDNA from isolated human islets that was pretested for insulin production; mRNA served as a negative control (&#8722;). RT, reverse transcriptase. <bold>b</bold> Western blot to detect P2X<sub>7</sub> in human islets. <bold>c</bold> Immunofluorescence to detect P2X<sub>7</sub> and insulin in human pancreatic islets cultured for 24&#160;h at 5.5&#160;mmol/l glucose. P2X<sub>7</sub> is shown in red and insulin, a marker for beta cells, in green. Co-localisation (&#8216;Merge&#8217;) is visible as yellow. The results are representative of at least three independent experiments using islets from three donors. <bold>d</bold> Paraffin-embedded human pancreatic sections from a lean non-diabetic control (first row), an obese control (second row), a lean patient with type 2 diabetes (third row) and an obese patient with type 2 diabetes (fourth row) were analysed for the presence of P2X<sub>7</sub> (shown in red) and insulin (green). Co-localisation is visible in yellow. The results represent five independent cases from each group</p></caption><graphic position="anchor" xlink:href="125_2009_1349_Fig1_HTML" id="MO1"/></fig>
###xml 163 168 <span type="species:ncbi:9606">human</span>
###xml 603 611 <span type="species:ncbi:9606">patients</span>
###xml 749 754 <span type="species:ncbi:9606">human</span>
###xml 793 801 <span type="species:ncbi:9606">patients</span>
###xml 866 874 <span type="species:ncbi:9606">patients</span>
###xml 1238 1243 <span type="species:ncbi:9606">human</span>
###xml 1393 1398 <span type="species:ncbi:9606">human</span>
###xml 1458 1463 <span type="species:ncbi:9606">human</span>
###xml 1765 1770 <span type="species:ncbi:9606">human</span>
###xml 1875 1882 <span type="species:ncbi:9606">patient</span>
###xml 1929 1936 <span type="species:ncbi:9606">patient</span>
P2X7 is produced in beta cells, upregulated in obesity and decreased in diabetes To investigate the role of P2X7 in islets, we analysed its production in isolated human islets. The presence of P2X7 transcripts is shown by mRNA analysis (Fig. 1a) and western blotting (Fig. 1b). The majority of the beta cells stained positive for P2X7 (Fig. 1c). We also found the presence of P2X7 in alpha cells (not shown). To analyse regulation of P2X7 in vivo, we compared staining and production of P2X7 in beta cells in pancreatic sections obtained at autopsy from both obese and lean non-diabetic individuals and patients with type 2 diabetes. Double immunostaining for P2X7 and insulin (Fig. 1d) confirmed the presence of P2X7 localised in the beta cells in human pancreatic sections from lean control patients (first row), which was highly upregulated in obese non-diabetic patients (second row). In contrast, in both lean (third row) and obese (fourth row) diabetic groups, P2X7 was barely detectable; no islet P2X7 receptors were found in any of the diabetic pancreases. Fig. 1P2X7 is produced in beta cells, upregulated in obesity and decreased in diabetes. a Agarose gel of the PCR products P2X7 and tubulin obtained using cDNA from isolated human islets that was pretested for insulin production; mRNA served as a negative control (-). RT, reverse transcriptase. b Western blot to detect P2X7 in human islets. c Immunofluorescence to detect P2X7 and insulin in human pancreatic islets cultured for 24 h at 5.5 mmol/l glucose. P2X7 is shown in red and insulin, a marker for beta cells, in green. Co-localisation ('Merge') is visible as yellow. The results are representative of at least three independent experiments using islets from three donors. d Paraffin-embedded human pancreatic sections from a lean non-diabetic control (first row), an obese control (second row), a lean patient with type 2 diabetes (third row) and an obese patient with type 2 diabetes (fourth row) were analysed for the presence of P2X7 (shown in red) and insulin (green). Co-localisation is visible in yellow. The results represent five independent cases from each group
###end p 29
###begin p 30
###xml 3 4 3 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 82 83 82 83 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 119 120 119 120 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 289 290 289 290 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 317 318 317 318 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 336 337 336 337 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 370 371 370 371 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 455 456 455 456 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 674 675 674 675 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 937 938 937 938 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 167 172 <span type="species:ncbi:9606">human</span>
###xml 322 327 <span type="species:ncbi:9606">human</span>
###xml 387 392 <span type="species:ncbi:9606">human</span>
###xml 694 699 <span type="species:ncbi:9606">human</span>
###xml 804 811 <span type="species:ncbi:9606">patient</span>
###xml 858 865 <span type="species:ncbi:9606">patient</span>
P2X7 is produced in beta cells, upregulated in obesity and decreased in diabetes. a Agarose gel of the PCR products P2X7 and tubulin obtained using cDNA from isolated human islets that was pretested for insulin production; mRNA served as a negative control (-). RT, reverse transcriptase. b Western blot to detect P2X7 in human islets. c Immunofluorescence to detect P2X7 and insulin in human pancreatic islets cultured for 24 h at 5.5 mmol/l glucose. P2X7 is shown in red and insulin, a marker for beta cells, in green. Co-localisation ('Merge') is visible as yellow. The results are representative of at least three independent experiments using islets from three donors. d Paraffin-embedded human pancreatic sections from a lean non-diabetic control (first row), an obese control (second row), a lean patient with type 2 diabetes (third row) and an obese patient with type 2 diabetes (fourth row) were analysed for the presence of P2X7 (shown in red) and insulin (green). Co-localisation is visible in yellow. The results represent five independent cases from each group
###end p 30
###begin p 31
###xml 3 4 3 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 0 96 0 96 <bold xmlns:xlink="http://www.w3.org/1999/xlink">P2X<sub>7</sub> is upregulated by short-term exposure to elevated glucose and NEFA in isolated human islets</bold>
###xml 129 130 129 130 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 276 277 276 277 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 372 374 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 423 424 423 424 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 435 437 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 597 599 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 943 944 939 940 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1041 1042 1037 1038 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1066 1068 1062 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 1137 1138 1133 1134 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1185 1186 1181 1182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 1234 1235 1230 1231 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1311 1317 1307 1313 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 1320 1321 1316 1317 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1415 1418 1411 1414 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a&#8211;d</bold>
###xml 1601 1602 1597 1598 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1635 1636 1631 1632 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1674 1675 1669 1670 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1715 1716 1710 1711 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1759 1760 1754 1755 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 1911 1912 1906 1907 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 2231 2232 2226 2227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2343 2344 2338 2339 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 2344 2348 2339 2343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2X7</italic>
###xml 2365 2366 2360 2361 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 2368 2369 2363 2364 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 2373 2374 2368 2369 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 2696 2697 2691 2692 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 2709 2710 2704 2705 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 2946 2951 2941 2946 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LINCO</italic>
###xml 3294 3295 3287 3288 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 3303 3306 3296 3299 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e&#8211;i</bold>
###xml 3317 3318 3310 3311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 3346 3347 3339 3340 <bold xmlns:xlink="http://www.w3.org/1999/xlink">j</bold>
###xml 3705 3706 3695 3696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 3760 3761 3750 3751 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1317 3848 1313 3838 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="32">P2X<sub>7</sub> is upregulated by short-term exposure to elevated glucose and NEFA in human isolated islets. <bold>a&#8211;d</bold> Freshly isolated human islets were grown on dishes coated with extracellular matrix until monolayer formation (72&#160;h). Uptake of the nucleic stain YO-PRO-1 was allowed by inducing P2X<sub>7</sub> activation via stimulation with <bold>a</bold> 100&#160;&#956;mol/l BzATP (black triangles), <bold>b</bold> 33.3&#160;mmol/l glucose (black triangles), <bold>c</bold> 11.1&#160;mmol/l glucose (black triangles) and <bold>d</bold> 0.5&#160;mmol/l palmitate at 5.5&#160;mmol/l glucose (black triangles), respectively, or inhibited with 30&#160;min pre-incubation with the specific inhibitor of P2X<sub>7</sub>, KN-62 (crosses), or apyrase (white squares). As the control, human islets were incubated in media containing 5.5&#160;mmol/l glucose (black squares). Quantification was accomplished by verifying YO-PRO-1 emission at 488&#160;nm and counting fluorescence nuclei per visual field (four fields per condition) every 5&#160;min for 1&#160;h; <italic>n</italic>&#8201;=&#8201;3 experiments from three different donors. Data are expressed as percentage of YO-PRO-positive islet cells. <bold>e</bold><italic>P2X7</italic> mRNA levels and <bold>f</bold>, <bold>g</bold> P2X<sub>7</sub> protein levels from human islets in response to incubation with 11.1&#160;mmol/l or 33.3&#160;mmol/l glucose or palmitate (NEFA) for 10&#160;min. The results are presented after normalising to tubulin mRNA levels and as relative numbers to the corresponding unstimulated control (5.5&#160;mmol/l glucose). Actin was used as loading control. <bold>h</bold> IL-1Ra and <bold>i</bold> insulin secretion from human islets exposed for 1&#160;h to elevated glucose concentrations or palmitic acid (NEFA) at 5.5&#160;mmol/l glucose with (black bars) or without (white bars) 30&#160;min pre-treatment with KN-62. IL-1Ra was analysed by the <italic>LINCO</italic>plex technology and insulin by ELISA from the same cell culture supernatant fractions, which were collected from three independent experiments from three donors from three dishes for each experiment. Data are shown as means of insulin divided by corresponding insulin content&#8201;&#177;&#8201;SE and normalised to control conditions at 5.5&#160;mmol/l glucose (<bold>i</bold> only). <bold>e&#8211;i</bold> Values on <italic>x</italic>-axis are glucose (mmol/l). <bold>j</bold> The rise in IL-1Ra was confirmed by a time-dependent experiment using isolated human islets exposed to 11.1 and 33.3&#160;mmol/l glucose and 0.5&#160;mmol/l palmitate (NEFA) for 30&#160;min to 24&#160;h. Western blot analysis was performed for IL-1Ra and &#946;-actin as loading control on the same blot. Representative blots from three experiments from three donors are shown. *<italic>p</italic>&#8201;&lt;&#8201;0.05 vs untreated control at 5.5&#160;mmol/l glucose; **<italic>p</italic>&#8201;&lt;&#8201;0.05 vs islets treated with BzATP, 11.1 or 33.3&#160;mmol/l glucose or NEFA, respectively</p>
###xml 1317 3848 1313 3838 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="32">P2X<sub>7</sub> is upregulated by short-term exposure to elevated glucose and NEFA in human isolated islets. <bold>a&#8211;d</bold> Freshly isolated human islets were grown on dishes coated with extracellular matrix until monolayer formation (72&#160;h). Uptake of the nucleic stain YO-PRO-1 was allowed by inducing P2X<sub>7</sub> activation via stimulation with <bold>a</bold> 100&#160;&#956;mol/l BzATP (black triangles), <bold>b</bold> 33.3&#160;mmol/l glucose (black triangles), <bold>c</bold> 11.1&#160;mmol/l glucose (black triangles) and <bold>d</bold> 0.5&#160;mmol/l palmitate at 5.5&#160;mmol/l glucose (black triangles), respectively, or inhibited with 30&#160;min pre-incubation with the specific inhibitor of P2X<sub>7</sub>, KN-62 (crosses), or apyrase (white squares). As the control, human islets were incubated in media containing 5.5&#160;mmol/l glucose (black squares). Quantification was accomplished by verifying YO-PRO-1 emission at 488&#160;nm and counting fluorescence nuclei per visual field (four fields per condition) every 5&#160;min for 1&#160;h; <italic>n</italic>&#8201;=&#8201;3 experiments from three different donors. Data are expressed as percentage of YO-PRO-positive islet cells. <bold>e</bold><italic>P2X7</italic> mRNA levels and <bold>f</bold>, <bold>g</bold> P2X<sub>7</sub> protein levels from human islets in response to incubation with 11.1&#160;mmol/l or 33.3&#160;mmol/l glucose or palmitate (NEFA) for 10&#160;min. The results are presented after normalising to tubulin mRNA levels and as relative numbers to the corresponding unstimulated control (5.5&#160;mmol/l glucose). Actin was used as loading control. <bold>h</bold> IL-1Ra and <bold>i</bold> insulin secretion from human islets exposed for 1&#160;h to elevated glucose concentrations or palmitic acid (NEFA) at 5.5&#160;mmol/l glucose with (black bars) or without (white bars) 30&#160;min pre-treatment with KN-62. IL-1Ra was analysed by the <italic>LINCO</italic>plex technology and insulin by ELISA from the same cell culture supernatant fractions, which were collected from three independent experiments from three donors from three dishes for each experiment. Data are shown as means of insulin divided by corresponding insulin content&#8201;&#177;&#8201;SE and normalised to control conditions at 5.5&#160;mmol/l glucose (<bold>i</bold> only). <bold>e&#8211;i</bold> Values on <italic>x</italic>-axis are glucose (mmol/l). <bold>j</bold> The rise in IL-1Ra was confirmed by a time-dependent experiment using isolated human islets exposed to 11.1 and 33.3&#160;mmol/l glucose and 0.5&#160;mmol/l palmitate (NEFA) for 30&#160;min to 24&#160;h. Western blot analysis was performed for IL-1Ra and &#946;-actin as loading control on the same blot. Representative blots from three experiments from three donors are shown. *<italic>p</italic>&#8201;&lt;&#8201;0.05 vs untreated control at 5.5&#160;mmol/l glucose; **<italic>p</italic>&#8201;&lt;&#8201;0.05 vs islets treated with BzATP, 11.1 or 33.3&#160;mmol/l glucose or NEFA, respectively</p></caption>
###xml 3848 3848 3838 3838 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="125_2009_1349_Fig2_HTML" id="MO2"/>
###xml 1311 3848 1307 3838 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="32">P2X<sub>7</sub> is upregulated by short-term exposure to elevated glucose and NEFA in human isolated islets. <bold>a&#8211;d</bold> Freshly isolated human islets were grown on dishes coated with extracellular matrix until monolayer formation (72&#160;h). Uptake of the nucleic stain YO-PRO-1 was allowed by inducing P2X<sub>7</sub> activation via stimulation with <bold>a</bold> 100&#160;&#956;mol/l BzATP (black triangles), <bold>b</bold> 33.3&#160;mmol/l glucose (black triangles), <bold>c</bold> 11.1&#160;mmol/l glucose (black triangles) and <bold>d</bold> 0.5&#160;mmol/l palmitate at 5.5&#160;mmol/l glucose (black triangles), respectively, or inhibited with 30&#160;min pre-incubation with the specific inhibitor of P2X<sub>7</sub>, KN-62 (crosses), or apyrase (white squares). As the control, human islets were incubated in media containing 5.5&#160;mmol/l glucose (black squares). Quantification was accomplished by verifying YO-PRO-1 emission at 488&#160;nm and counting fluorescence nuclei per visual field (four fields per condition) every 5&#160;min for 1&#160;h; <italic>n</italic>&#8201;=&#8201;3 experiments from three different donors. Data are expressed as percentage of YO-PRO-positive islet cells. <bold>e</bold><italic>P2X7</italic> mRNA levels and <bold>f</bold>, <bold>g</bold> P2X<sub>7</sub> protein levels from human islets in response to incubation with 11.1&#160;mmol/l or 33.3&#160;mmol/l glucose or palmitate (NEFA) for 10&#160;min. The results are presented after normalising to tubulin mRNA levels and as relative numbers to the corresponding unstimulated control (5.5&#160;mmol/l glucose). Actin was used as loading control. <bold>h</bold> IL-1Ra and <bold>i</bold> insulin secretion from human islets exposed for 1&#160;h to elevated glucose concentrations or palmitic acid (NEFA) at 5.5&#160;mmol/l glucose with (black bars) or without (white bars) 30&#160;min pre-treatment with KN-62. IL-1Ra was analysed by the <italic>LINCO</italic>plex technology and insulin by ELISA from the same cell culture supernatant fractions, which were collected from three independent experiments from three donors from three dishes for each experiment. Data are shown as means of insulin divided by corresponding insulin content&#8201;&#177;&#8201;SE and normalised to control conditions at 5.5&#160;mmol/l glucose (<bold>i</bold> only). <bold>e&#8211;i</bold> Values on <italic>x</italic>-axis are glucose (mmol/l). <bold>j</bold> The rise in IL-1Ra was confirmed by a time-dependent experiment using isolated human islets exposed to 11.1 and 33.3&#160;mmol/l glucose and 0.5&#160;mmol/l palmitate (NEFA) for 30&#160;min to 24&#160;h. Western blot analysis was performed for IL-1Ra and &#946;-actin as loading control on the same blot. Representative blots from three experiments from three donors are shown. *<italic>p</italic>&#8201;&lt;&#8201;0.05 vs untreated control at 5.5&#160;mmol/l glucose; **<italic>p</italic>&#8201;&lt;&#8201;0.05 vs islets treated with BzATP, 11.1 or 33.3&#160;mmol/l glucose or NEFA, respectively</p></caption><graphic position="anchor" xlink:href="125_2009_1349_Fig2_HTML" id="MO2"/></fig>
###xml 3882 3883 3872 3873 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 3937 3938 3927 3928 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 4064 4065 4054 4055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 4104 4105 4094 4095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 4187 4188 4177 4178 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 4390 4391 4380 4381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 4634 4635 4624 4625 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 4659 4660 4649 4650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 4683 4684 4673 4674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 4709 4710 4699 4700 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 4793 4794 4783 4784 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 4840 4842 4830 4832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 4889 4890 4879 4880 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 4970 4974 4960 4964 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2X7</italic>
###xml 4993 4994 4983 4984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 5186 5187 5176 5177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 5272 5273 5262 5263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 5492 5493 5479 5480 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 5550 5552 5537 5539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 5594 5595 5581 5582 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 5663 5667 5650 5654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2X7</italic>
###xml 5680 5681 5667 5668 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 5871 5872 5858 5859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 5874 5875 5861 5862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 5977 5978 5964 5965 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 6088 6090 6075 6077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 6092 6094 6079 6081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 6246 6247 6233 6234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 6536 6537 6522 6523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 6868 6869 6854 6855 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 84 89 <span type="species:ncbi:9606">human</span>
###xml 619 624 <span type="species:ncbi:9606">human</span>
###xml 1392 1397 <span type="species:ncbi:9606">human</span>
###xml 1436 1441 <span type="species:ncbi:9606">human</span>
###xml 1975 1980 <span type="species:ncbi:9606">human</span>
###xml 2395 2400 <span type="species:ncbi:9606">human</span>
###xml 2734 2739 <span type="species:ncbi:9606">human</span>
###xml 3427 3432 <span type="species:ncbi:9606">human</span>
###xml 6664 6669 <span type="species:ncbi:9606">human</span>
P2X7 is upregulated by short-term exposure to elevated glucose and NEFA in isolated human islets The functional production of P2X7 in beta cells was verified with the nucleic acid stain YO-PRO-1 (0.375 kDa, Molecular Probes). This is based on the pore-forming character of P2X7; its activation leads to the formation of a pore that is passable to molecules up to 0.9 kDa [24]. YO-PRO-1 has been widely used to visualise P2X7 activity [15], although YO-PRO-1 can also access the beta cell in the presence of membrane blebbing during apoptosis and is also used for the detection of apoptotic cells [25]. Freshly isolated human islets plated on dishes coated with extracellular matrix were loaded with 10 mumol/l YO-PRO-1 10 min before receptor activation by addition of 100 mumol/l benzoyl ATP (BzATP). Within 5 min of exposure, YO-PRO-1 was taken up by 45 +/- 6.01% of the islet cells; this was inhibited by pre-incubation with the specific P2X7 inhibitor KN-62, which has been demonstrated to block YO-PRO-1 uptake initiated by prolonged P2X7 activation previously [26]. The ATP-degrading enzyme apyrase (a less specific inhibitor of P2X7) had similar effects on YO-PRO-1 uptake (Fig. 2a). These data show production of functional P2X7 in islets. In contrast, <5% of the untreated cells showed YO-PRO-1 uptake. Fig. 2P2X7 is upregulated by short-term exposure to elevated glucose and NEFA in human isolated islets. a-d Freshly isolated human islets were grown on dishes coated with extracellular matrix until monolayer formation (72 h). Uptake of the nucleic stain YO-PRO-1 was allowed by inducing P2X7 activation via stimulation with a 100 mumol/l BzATP (black triangles), b 33.3 mmol/l glucose (black triangles), c 11.1 mmol/l glucose (black triangles) and d 0.5 mmol/l palmitate at 5.5 mmol/l glucose (black triangles), respectively, or inhibited with 30 min pre-incubation with the specific inhibitor of P2X7, KN-62 (crosses), or apyrase (white squares). As the control, human islets were incubated in media containing 5.5 mmol/l glucose (black squares). Quantification was accomplished by verifying YO-PRO-1 emission at 488 nm and counting fluorescence nuclei per visual field (four fields per condition) every 5 min for 1 h; n = 3 experiments from three different donors. Data are expressed as percentage of YO-PRO-positive islet cells. eP2X7 mRNA levels and f, g P2X7 protein levels from human islets in response to incubation with 11.1 mmol/l or 33.3 mmol/l glucose or palmitate (NEFA) for 10 min. The results are presented after normalising to tubulin mRNA levels and as relative numbers to the corresponding unstimulated control (5.5 mmol/l glucose). Actin was used as loading control. h IL-1Ra and i insulin secretion from human islets exposed for 1 h to elevated glucose concentrations or palmitic acid (NEFA) at 5.5 mmol/l glucose with (black bars) or without (white bars) 30 min pre-treatment with KN-62. IL-1Ra was analysed by the LINCOplex technology and insulin by ELISA from the same cell culture supernatant fractions, which were collected from three independent experiments from three donors from three dishes for each experiment. Data are shown as means of insulin divided by corresponding insulin content +/- SE and normalised to control conditions at 5.5 mmol/l glucose (i only). e-i Values on x-axis are glucose (mmol/l). j The rise in IL-1Ra was confirmed by a time-dependent experiment using isolated human islets exposed to 11.1 and 33.3 mmol/l glucose and 0.5 mmol/l palmitate (NEFA) for 30 min to 24 h. Western blot analysis was performed for IL-1Ra and beta-actin as loading control on the same blot. Representative blots from three experiments from three donors are shown. *p < 0.05 vs untreated control at 5.5 mmol/l glucose; **p < 0.05 vs islets treated with BzATP, 11.1 or 33.3 mmol/l glucose or NEFA, respectivelyAs we have observed changes in P2X7 levels in obesity and diabetes, we tested whether P2X7 is activated by a diabetic milieu in culture. Islets were exposed to increased glucose concentrations (5.5-33.3 mmol/l, Fig. 2b,c) or 0.5 mmol/l palmitic acid (Fig. 2d) for 10 min after YO-PRO-1 loading. Elevated glucose concentration activated P2X7, as did palmitic acid; we observed a nine-fold activation by 33.3 mmol/l glucose, six-fold activation by 11.1 mmol/l glucose and a nine-fold activation by palmitic acid within 5 to 10 min of exposure (p < 0.001). Peak levels slightly decreased after 15 min exposure, but remained elevated compared with control conditions throughout the 1 h incubation period, similar to the finding with BzATP stimulation. In all assays, co-culture with the P2X7 inhibitors KN-62 (Fig. 2a-d) and apyrase (Fig. 2a, b, d), reduced the P2X7 activation induced by BzATP, elevated glucose or palmitic acid.As BzATP evokes P2X7 effects very briefly, even within 1 to 30 s [27], we wanted to see if there is a change in P2X7 level in response to the activation. Elevated glucose concentrations increased P2X7 mRNA levels (Fig. 2e: 1.7-fold increase with 11.1 mmol/l glucose, 2.5-fold increase with 33.3 mmol/l glucose and 1.8-fold increase with palmitic acid, compared with control [untreated, with 5.5 mmol/l glucose], p < 0.05) after 10 min of exposure. This was confirmed by western blot analysis (Fig. 2f, g). Changes in mRNA level and protein production were detected within this short time, whereas values returned to basal after 24 h of exposure (not shown). Previous reports show that IL-1beta induces increases in P2X7 at 6 h, with levels decreasing after 48 h of treatment [15]. One explanation for the increase in P2X7 within this narrow timeframe would be a rapid de novo synthesis of P2X7 mRNA and P2X7 protein, given weight by its relatively small size (595 amino acids/68 kDa).Recently, we have shown that IL-1Ra can protect from impaired beta cell function and death in vivo and in vitro [4, 8]. The mechanisms of its secretion from the beta cell are unknown. We tested whether activation of P2X7 leads to IL-1Ra secretion. Long-term glucose exposure had no effect on IL-1Ra secretion (data not shown and [28, 29]). But short-term (30 min) exposure of islets to elevated glucose, palmitic acid or BzATP induced IL-1Ra secretion, which was inhibited by KN-62 (Fig. 2h). Analysis of insulin secretion in the same supernatant fractions showed similar regulation of insulin secretion. Elevated glucose levels (11.1 and 33.3 mmol/l), 0.5 mmol/l palmitic acid and 100 mumol/l BzATP induced insulin secretion, which was prevented by co-culture with KN-62 (Fig. 2i).Regulation of IL-1Ra production by glucose and palmitic acid was confirmed by western blot analysis. Short-term exposure of human islets to elevated glucose and palmitic acid (30 min-8 h) induced IL-1Ra secretion, whereas no differences were observed at 24 h treatment. These data indicate a parallel induction of IL-1Ra and P2X7 in pancreatic islets.
###end p 31
###begin p 32
###xml 3 4 3 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 98 101 98 101 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a&#8211;d</bold>
###xml 284 285 284 285 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 318 319 318 319 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 357 358 356 357 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 398 399 397 398 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 442 443 441 442 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 594 595 593 594 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 914 915 913 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1026 1027 1025 1026 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 1027 1031 1026 1030 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2X7</italic>
###xml 1048 1049 1047 1048 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 1051 1052 1050 1051 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 1056 1057 1055 1056 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1379 1380 1378 1379 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 1392 1393 1391 1392 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 1629 1634 1628 1633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LINCO</italic>
###xml 1977 1978 1974 1975 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 1986 1989 1983 1986 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e&#8211;i</bold>
###xml 2000 2001 1997 1998 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 2029 2030 2026 2027 <bold xmlns:xlink="http://www.w3.org/1999/xlink">j</bold>
###xml 2388 2389 2382 2383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2443 2444 2437 2438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 75 80 <span type="species:ncbi:9606">human</span>
###xml 119 124 <span type="species:ncbi:9606">human</span>
###xml 658 663 <span type="species:ncbi:9606">human</span>
###xml 1078 1083 <span type="species:ncbi:9606">human</span>
###xml 1417 1422 <span type="species:ncbi:9606">human</span>
###xml 2110 2115 <span type="species:ncbi:9606">human</span>
P2X7 is upregulated by short-term exposure to elevated glucose and NEFA in human isolated islets. a-d Freshly isolated human islets were grown on dishes coated with extracellular matrix until monolayer formation (72 h). Uptake of the nucleic stain YO-PRO-1 was allowed by inducing P2X7 activation via stimulation with a 100 mumol/l BzATP (black triangles), b 33.3 mmol/l glucose (black triangles), c 11.1 mmol/l glucose (black triangles) and d 0.5 mmol/l palmitate at 5.5 mmol/l glucose (black triangles), respectively, or inhibited with 30 min pre-incubation with the specific inhibitor of P2X7, KN-62 (crosses), or apyrase (white squares). As the control, human islets were incubated in media containing 5.5 mmol/l glucose (black squares). Quantification was accomplished by verifying YO-PRO-1 emission at 488 nm and counting fluorescence nuclei per visual field (four fields per condition) every 5 min for 1 h; n = 3 experiments from three different donors. Data are expressed as percentage of YO-PRO-positive islet cells. eP2X7 mRNA levels and f, g P2X7 protein levels from human islets in response to incubation with 11.1 mmol/l or 33.3 mmol/l glucose or palmitate (NEFA) for 10 min. The results are presented after normalising to tubulin mRNA levels and as relative numbers to the corresponding unstimulated control (5.5 mmol/l glucose). Actin was used as loading control. h IL-1Ra and i insulin secretion from human islets exposed for 1 h to elevated glucose concentrations or palmitic acid (NEFA) at 5.5 mmol/l glucose with (black bars) or without (white bars) 30 min pre-treatment with KN-62. IL-1Ra was analysed by the LINCOplex technology and insulin by ELISA from the same cell culture supernatant fractions, which were collected from three independent experiments from three donors from three dishes for each experiment. Data are shown as means of insulin divided by corresponding insulin content +/- SE and normalised to control conditions at 5.5 mmol/l glucose (i only). e-i Values on x-axis are glucose (mmol/l). j The rise in IL-1Ra was confirmed by a time-dependent experiment using isolated human islets exposed to 11.1 and 33.3 mmol/l glucose and 0.5 mmol/l palmitate (NEFA) for 30 min to 24 h. Western blot analysis was performed for IL-1Ra and beta-actin as loading control on the same blot. Representative blots from three experiments from three donors are shown. *p < 0.05 vs untreated control at 5.5 mmol/l glucose; **p < 0.05 vs islets treated with BzATP, 11.1 or 33.3 mmol/l glucose or NEFA, respectively
###end p 32
###begin p 33
###xml 3 4 3 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 0 134 0 134 <bold xmlns:xlink="http://www.w3.org/1999/xlink">P2X<sub>7</sub>-deficient mice have impaired glucose tolerance, beta cell mass and function and fail to adapt IL-1Ra secretion to a high-fat diet</bold>
###xml 153 154 153 154 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 279 280 279 280 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 313 314 313 314 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 465 466 465 466 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 484 485 484 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 766 767 762 763 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 777 778 773 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 788 794 784 790 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 797 798 793 794 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 936 937 932 933 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1105 1106 1101 1102 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1136 1137 1132 1133 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1218 1219 1214 1215 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1359 1360 1355 1356 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1390 1391 1386 1387 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1451 1452 1447 1448 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1670 1671 1666 1667 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 1756 1757 1752 1753 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1780 1781 1776 1777 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 2007 2008 2003 2004 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 2038 2039 2034 2035 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 2066 2067 2062 2063 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 2158 2159 2154 2155 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 2220 2221 2216 2217 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 2334 2335 2330 2331 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 2353 2354 2349 2350 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 2411 2412 2407 2408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2713 2714 2709 2710 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 3159 3160 3151 3152 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 3171 3172 3163 3164 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 3286 3287 3278 3279 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 3298 3299 3290 3291 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 3299 3300 3291 3292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 3336 3337 3328 3329 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 3337 3338 3329 3330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 3357 3358 3349 3350 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 3375 3376 3367 3368 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 3376 3377 3368 3369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 3408 3409 3400 3401 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 3409 3410 3401 3402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 794 3454 790 3446 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="34">P2X<sub>7</sub>-deficient mice have impaired glucose tolerance and beta cell mass and function and do not adapt IL-1Ra secretion during a high-fat diet. <bold>a</bold> Changes in body weight in response to the HFD were measured every week during the study and results are shown from WT-ND (black squares), WT-HFD (black triangles), P2X<sub>7</sub>-KO-ND (white squares) and P2X<sub>7</sub>-KO-HFD (white triangles) mice from three different studies (12 mice per group). <bold>b</bold> Blood glucose following i.p. injection of glucose at 1&#160;g/kg body weight are shown from WT-ND (black squares), WT-HFD (black triangles), P2X<sub>7</sub>-KO-ND (white squares) and P2X<sub>7</sub>-KO-HFD (white triangles) mice after 12&#160;weeks of treatment. <bold>c</bold> Serum insulin levels following i.p. injection of glucose at 1&#160;g/kg body weight are shown from mice after 12&#160;weeks of treatment; open bars show levels at 0&#160;min, solid bars show levels at 30&#160;min. The stimulatory index (<bold>d</bold>) denotes the ratio of stimulated and basal insulin levels in WT (black bars) and P2X<sub>7</sub>-KO (white bars) mice. <bold>e</bold> Blood glucose concentrations in mice undergoing an insulin tolerance test after 12&#160;weeks of treatment. Insulin was injected i.p. at a concentration of 0.5&#160;U/kg body weight; WT-ND (black squares), WT-HFD (black triangles), P2X<sub>7</sub>-KO-ND (white squares) and P2X<sub>7</sub>-KO-HFD (white triangles). <bold>f</bold> Immunostaining for insulin in green (magnification &#215;125) shows disrupted islets in the P2X<sub>7</sub>-KO mice, which was confirmed by analysis of beta cell mass (<bold>g</bold>) in tissue sections spanning the width of the whole pancreas from (1) WT-ND and (2) WT-HFD (black bars), (3) P2X<sub>7</sub>-KO-ND and (4) P2X<sub>7</sub>-KO-HFD (white bars) mice after 12 and 16&#160;weeks of diet (<italic>n</italic>&#8201;=&#8201;4 mice for each group). Beta cell mass per pancreas was estimated as the product of the relative cross-sectional area of beta cells (determined by quantification of the cross-sectional area occupied by beta cells divided by the cross-sectional area of total tissue) and the weight of the pancreas. <bold>h</bold> Analysis of beta cell apoptosis by triple staining for TUNEL, insulin and DAPI (a fluorescent stain that binds strongly to DNA) was performed on the same pancreatic sections. Results are expressed as percentage of TUNEL-positive beta cells&#8201;&#177;&#8201;SE normalised to control ND islets. The mean number of beta cells scored was 6,239&#8201;&#177;&#8201;1,035 for each treatment condition from six individual mice per treatment (solid bars represent WT, open bars P2X<sub>7</sub>-KO mice). <bold>i</bold> Serum levels of IL-1Ra were measured after 4, 8, 12 and 16&#160;weeks of diet (black bars represent WT, white bars P2X<sub>7</sub>-KO mice). <sup>a</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 between mice on ND and HFD; <sup>b</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 between P2X<sub>7</sub>-KO and WT mice; <sup>c</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 GSIS: 30&#160;min vs 0&#160;min; <sup>d</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 beta cell mass: 16&#160;weeks vs 12&#160;weeks</p>
###xml 794 3454 790 3446 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="34">P2X<sub>7</sub>-deficient mice have impaired glucose tolerance and beta cell mass and function and do not adapt IL-1Ra secretion during a high-fat diet. <bold>a</bold> Changes in body weight in response to the HFD were measured every week during the study and results are shown from WT-ND (black squares), WT-HFD (black triangles), P2X<sub>7</sub>-KO-ND (white squares) and P2X<sub>7</sub>-KO-HFD (white triangles) mice from three different studies (12 mice per group). <bold>b</bold> Blood glucose following i.p. injection of glucose at 1&#160;g/kg body weight are shown from WT-ND (black squares), WT-HFD (black triangles), P2X<sub>7</sub>-KO-ND (white squares) and P2X<sub>7</sub>-KO-HFD (white triangles) mice after 12&#160;weeks of treatment. <bold>c</bold> Serum insulin levels following i.p. injection of glucose at 1&#160;g/kg body weight are shown from mice after 12&#160;weeks of treatment; open bars show levels at 0&#160;min, solid bars show levels at 30&#160;min. The stimulatory index (<bold>d</bold>) denotes the ratio of stimulated and basal insulin levels in WT (black bars) and P2X<sub>7</sub>-KO (white bars) mice. <bold>e</bold> Blood glucose concentrations in mice undergoing an insulin tolerance test after 12&#160;weeks of treatment. Insulin was injected i.p. at a concentration of 0.5&#160;U/kg body weight; WT-ND (black squares), WT-HFD (black triangles), P2X<sub>7</sub>-KO-ND (white squares) and P2X<sub>7</sub>-KO-HFD (white triangles). <bold>f</bold> Immunostaining for insulin in green (magnification &#215;125) shows disrupted islets in the P2X<sub>7</sub>-KO mice, which was confirmed by analysis of beta cell mass (<bold>g</bold>) in tissue sections spanning the width of the whole pancreas from (1) WT-ND and (2) WT-HFD (black bars), (3) P2X<sub>7</sub>-KO-ND and (4) P2X<sub>7</sub>-KO-HFD (white bars) mice after 12 and 16&#160;weeks of diet (<italic>n</italic>&#8201;=&#8201;4 mice for each group). Beta cell mass per pancreas was estimated as the product of the relative cross-sectional area of beta cells (determined by quantification of the cross-sectional area occupied by beta cells divided by the cross-sectional area of total tissue) and the weight of the pancreas. <bold>h</bold> Analysis of beta cell apoptosis by triple staining for TUNEL, insulin and DAPI (a fluorescent stain that binds strongly to DNA) was performed on the same pancreatic sections. Results are expressed as percentage of TUNEL-positive beta cells&#8201;&#177;&#8201;SE normalised to control ND islets. The mean number of beta cells scored was 6,239&#8201;&#177;&#8201;1,035 for each treatment condition from six individual mice per treatment (solid bars represent WT, open bars P2X<sub>7</sub>-KO mice). <bold>i</bold> Serum levels of IL-1Ra were measured after 4, 8, 12 and 16&#160;weeks of diet (black bars represent WT, white bars P2X<sub>7</sub>-KO mice). <sup>a</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 between mice on ND and HFD; <sup>b</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 between P2X<sub>7</sub>-KO and WT mice; <sup>c</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 GSIS: 30&#160;min vs 0&#160;min; <sup>d</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 beta cell mass: 16&#160;weeks vs 12&#160;weeks</p></caption>
###xml 3454 3454 3446 3446 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="125_2009_1349_Fig3_HTML" id="MO3"/>
###xml 788 3454 784 3446 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="34">P2X<sub>7</sub>-deficient mice have impaired glucose tolerance and beta cell mass and function and do not adapt IL-1Ra secretion during a high-fat diet. <bold>a</bold> Changes in body weight in response to the HFD were measured every week during the study and results are shown from WT-ND (black squares), WT-HFD (black triangles), P2X<sub>7</sub>-KO-ND (white squares) and P2X<sub>7</sub>-KO-HFD (white triangles) mice from three different studies (12 mice per group). <bold>b</bold> Blood glucose following i.p. injection of glucose at 1&#160;g/kg body weight are shown from WT-ND (black squares), WT-HFD (black triangles), P2X<sub>7</sub>-KO-ND (white squares) and P2X<sub>7</sub>-KO-HFD (white triangles) mice after 12&#160;weeks of treatment. <bold>c</bold> Serum insulin levels following i.p. injection of glucose at 1&#160;g/kg body weight are shown from mice after 12&#160;weeks of treatment; open bars show levels at 0&#160;min, solid bars show levels at 30&#160;min. The stimulatory index (<bold>d</bold>) denotes the ratio of stimulated and basal insulin levels in WT (black bars) and P2X<sub>7</sub>-KO (white bars) mice. <bold>e</bold> Blood glucose concentrations in mice undergoing an insulin tolerance test after 12&#160;weeks of treatment. Insulin was injected i.p. at a concentration of 0.5&#160;U/kg body weight; WT-ND (black squares), WT-HFD (black triangles), P2X<sub>7</sub>-KO-ND (white squares) and P2X<sub>7</sub>-KO-HFD (white triangles). <bold>f</bold> Immunostaining for insulin in green (magnification &#215;125) shows disrupted islets in the P2X<sub>7</sub>-KO mice, which was confirmed by analysis of beta cell mass (<bold>g</bold>) in tissue sections spanning the width of the whole pancreas from (1) WT-ND and (2) WT-HFD (black bars), (3) P2X<sub>7</sub>-KO-ND and (4) P2X<sub>7</sub>-KO-HFD (white bars) mice after 12 and 16&#160;weeks of diet (<italic>n</italic>&#8201;=&#8201;4 mice for each group). Beta cell mass per pancreas was estimated as the product of the relative cross-sectional area of beta cells (determined by quantification of the cross-sectional area occupied by beta cells divided by the cross-sectional area of total tissue) and the weight of the pancreas. <bold>h</bold> Analysis of beta cell apoptosis by triple staining for TUNEL, insulin and DAPI (a fluorescent stain that binds strongly to DNA) was performed on the same pancreatic sections. Results are expressed as percentage of TUNEL-positive beta cells&#8201;&#177;&#8201;SE normalised to control ND islets. The mean number of beta cells scored was 6,239&#8201;&#177;&#8201;1,035 for each treatment condition from six individual mice per treatment (solid bars represent WT, open bars P2X<sub>7</sub>-KO mice). <bold>i</bold> Serum levels of IL-1Ra were measured after 4, 8, 12 and 16&#160;weeks of diet (black bars represent WT, white bars P2X<sub>7</sub>-KO mice). <sup>a</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 between mice on ND and HFD; <sup>b</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 between P2X<sub>7</sub>-KO and WT mice; <sup>c</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 GSIS: 30&#160;min vs 0&#160;min; <sup>d</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 beta cell mass: 16&#160;weeks vs 12&#160;weeks</p></caption><graphic position="anchor" xlink:href="125_2009_1349_Fig3_HTML" id="MO3"/></fig>
###xml 3604 3605 3596 3597 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 3740 3741 3732 3733 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 3754 3755 3746 3747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 3758 3759 3750 3751 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 3854 3855 3846 3847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 3963 3965 3955 3957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 4018 4019 4010 4011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 4057 4058 4049 4050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 4061 4062 4053 4054 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 4233 4234 4225 4226 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 4244 4245 4236 4237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 4360 4361 4352 4353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 4364 4365 4356 4357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 4390 4391 4382 4383 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 4511 4512 4503 4504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 4515 4516 4507 4508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 4530 4531 4522 4523 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 4608 4609 4600 4601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 4647 4648 4639 4640 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 5079 5080 5071 5072 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 5104 5105 5096 5097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 5369 5370 5361 5362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 5524 5525 5516 5517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 5539 5540 5531 5532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 5562 5563 5554 5555 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 5690 5691 5682 5683 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 5733 5734 5725 5726 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 5899 5900 5891 5892 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 5916 5917 5908 5909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 6117 6118 6109 6110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 6626 6627 6618 6619 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 6707 6708 6699 6700 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 6743 6744 6735 6736 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 6758 6759 6750 6751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 6769 6770 6761 6762 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 6849 6850 6841 6842 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 6920 6921 6912 6913 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 7078 7079 7070 7071 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 7543 7544 7535 7536 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 7675 7676 7667 7668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 8019 8020 8005 8006 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 15 19 <span type="species:ncbi:10090">mice</span>
###xml 169 174 <span type="species:ncbi:9606">human</span>
###xml 284 288 <span type="species:ncbi:10090">mice</span>
###xml 318 322 <span type="species:ncbi:10090">mice</span>
###xml 368 372 <span type="species:ncbi:10090">Mice</span>
###xml 678 682 <span type="species:ncbi:10090">mice</span>
###xml 726 730 <span type="species:ncbi:10090">mice</span>
###xml 771 775 <span type="species:ncbi:10090">mice</span>
###xml 809 813 <span type="species:ncbi:10090">mice</span>
###xml 1163 1167 <span type="species:ncbi:10090">mice</span>
###xml 1201 1205 <span type="species:ncbi:10090">mice</span>
###xml 1417 1421 <span type="species:ncbi:10090">mice</span>
###xml 1547 1551 <span type="species:ncbi:10090">mice</span>
###xml 1774 1778 <span type="species:ncbi:10090">mice</span>
###xml 1814 1818 <span type="species:ncbi:10090">mice</span>
###xml 2163 2167 <span type="species:ncbi:10090">mice</span>
###xml 2375 2379 <span type="species:ncbi:10090">mice</span>
###xml 2417 2421 <span type="species:ncbi:10090">mice</span>
###xml 3101 3105 <span type="species:ncbi:10090">mice</span>
###xml 3164 3168 <span type="species:ncbi:10090">mice</span>
###xml 3291 3295 <span type="species:ncbi:10090">mice</span>
###xml 3316 3320 <span type="species:ncbi:10090">mice</span>
###xml 3369 3373 <span type="species:ncbi:10090">mice</span>
###xml 3609 3613 <span type="species:ncbi:10090">mice</span>
###xml 4099 4103 <span type="species:ncbi:10090">mice</span>
###xml 4119 4123 <span type="species:ncbi:10090">mice</span>
###xml 4198 4202 <span type="species:ncbi:10090">mice</span>
###xml 4238 4242 <span type="species:ncbi:10090">mice</span>
###xml 4270 4274 <span type="species:ncbi:10090">mice</span>
###xml 4395 4399 <span type="species:ncbi:10090">mice</span>
###xml 4538 4542 <span type="species:ncbi:10090">mice</span>
###xml 4602 4606 <span type="species:ncbi:10090">mice</span>
###xml 4652 4656 <span type="species:ncbi:10090">mice</span>
###xml 4949 4953 <span type="species:ncbi:10090">mice</span>
###xml 5048 5052 <span type="species:ncbi:10090">mice</span>
###xml 5462 5466 <span type="species:ncbi:10090">mice</span>
###xml 5567 5571 <span type="species:ncbi:10090">mice</span>
###xml 5695 5699 <span type="species:ncbi:10090">mice</span>
###xml 5741 5745 <span type="species:ncbi:10090">mice</span>
###xml 5828 5832 <span type="species:ncbi:10090">mice</span>
###xml 6034 6038 <span type="species:ncbi:10090">mice</span>
###xml 6263 6267 <span type="species:ncbi:10090">mice</span>
###xml 6635 6639 <span type="species:ncbi:10090">mice</span>
###xml 6854 6858 <span type="species:ncbi:10090">mice</span>
###xml 6925 6929 <span type="species:ncbi:10090">mice</span>
###xml 6975 6979 <span type="species:ncbi:10090">mice</span>
###xml 7086 7090 <span type="species:ncbi:10090">mice</span>
###xml 7192 7196 <span type="species:ncbi:10090">mice</span>
###xml 7548 7552 <span type="species:ncbi:10090">mice</span>
###xml 7752 7757 <span type="species:ncbi:10090">mouse</span>
###xml 7950 7954 <span type="species:ncbi:10090">mice</span>
###xml 8024 8028 <span type="species:ncbi:10090">mice</span>
P2X7-deficient mice have impaired glucose tolerance, beta cell mass and function and fail to adapt IL-1Ra secretion to a high-fat diet The changes in P2X7 activation in human islets in vitro were compared with glucose tolerance, beta cell survival and IL-1Ra secretion in the P2X7-KO mice. Male C57Bl/6 WT and P2X7-KO mice were fed an ND or an HFD for up to 16 weeks. Mice fed the HFD gained more weight than the ND control group; this was not influenced by the P2X7-deficiency (Fig. 3a). Before and throughout the treatment period, we measured the fasting and fed blood glucose level every 4 weeks. Average fasted glucose levels before the beginning of the study in 5-week-old mice were 3.88 +/- 0.33 mmol/l in the wild-type mice and 5.27 +/- 0.44 mmol/l in the P2X7-KO mice (p < 0.05). Fig. 3P2X7-deficient mice have impaired glucose tolerance and beta cell mass and function and do not adapt IL-1Ra secretion during a high-fat diet. a Changes in body weight in response to the HFD were measured every week during the study and results are shown from WT-ND (black squares), WT-HFD (black triangles), P2X7-KO-ND (white squares) and P2X7-KO-HFD (white triangles) mice from three different studies (12 mice per group). b Blood glucose following i.p. injection of glucose at 1 g/kg body weight are shown from WT-ND (black squares), WT-HFD (black triangles), P2X7-KO-ND (white squares) and P2X7-KO-HFD (white triangles) mice after 12 weeks of treatment. c Serum insulin levels following i.p. injection of glucose at 1 g/kg body weight are shown from mice after 12 weeks of treatment; open bars show levels at 0 min, solid bars show levels at 30 min. The stimulatory index (d) denotes the ratio of stimulated and basal insulin levels in WT (black bars) and P2X7-KO (white bars) mice. e Blood glucose concentrations in mice undergoing an insulin tolerance test after 12 weeks of treatment. Insulin was injected i.p. at a concentration of 0.5 U/kg body weight; WT-ND (black squares), WT-HFD (black triangles), P2X7-KO-ND (white squares) and P2X7-KO-HFD (white triangles). f Immunostaining for insulin in green (magnification x125) shows disrupted islets in the P2X7-KO mice, which was confirmed by analysis of beta cell mass (g) in tissue sections spanning the width of the whole pancreas from (1) WT-ND and (2) WT-HFD (black bars), (3) P2X7-KO-ND and (4) P2X7-KO-HFD (white bars) mice after 12 and 16 weeks of diet (n = 4 mice for each group). Beta cell mass per pancreas was estimated as the product of the relative cross-sectional area of beta cells (determined by quantification of the cross-sectional area occupied by beta cells divided by the cross-sectional area of total tissue) and the weight of the pancreas. h Analysis of beta cell apoptosis by triple staining for TUNEL, insulin and DAPI (a fluorescent stain that binds strongly to DNA) was performed on the same pancreatic sections. Results are expressed as percentage of TUNEL-positive beta cells +/- SE normalised to control ND islets. The mean number of beta cells scored was 6,239 +/- 1,035 for each treatment condition from six individual mice per treatment (solid bars represent WT, open bars P2X7-KO mice). i Serum levels of IL-1Ra were measured after 4, 8, 12 and 16 weeks of diet (black bars represent WT, white bars P2X7-KO mice). ap < 0.05 between mice on ND and HFD; bp < 0.05 between P2X7-KO and WT mice; cp < 0.05 GSIS: 30 min vs 0 min; dp < 0.05 beta cell mass: 16 weeks vs 12 weeksAfter 12 weeks of the diet, high-fat feeding increased glucose levels and impaired glucose tolerance. The highest glucose levels were found in the P2X7-KO mice fed an HFD, with differences significant at all time points during an IPGTT compared with all other groups (WT-ND, WT-HFD, P2X7-KO-ND; Fig. 3b, p < 0.01). Glucose tolerance further deteriorated after 16 weeks of HFD diet (not shown).Figure 3c shows serum insulin levels during an IPGTT after 12 weeks of diet and treatment. As previously described [30], high-fat feeding resulted in hyperglycaemia (Fig. 3b) as well as hyperinsulinaemia (Fig. 3c, p < 0.001) compared with control diet mice. Compared with mice consuming an ND, fasted insulin levels were 3.4-fold higher in HFD-fed WT mice and 5.7-fold higher in the P2X7-KO mice (p < 0.01). The HFD-fed WT mice had a much lower capacity to increase their glucose-stimulated insulin release (Fig. 3d, p < 0.01), whereas the P2X7-KO mice on the HFD completely failed to further increase their insulin levels in response to a glucose challenge (Fig. 3d, p < 0.001). P2X7-KO-ND mice had a 1.3-fold lower stimulatory index than the WT control mice (p < 0.05). These data indicate that P2X7-KO mice have an impaired beta cell function, which deteriorates under the challenge of an HFD treatment.To determine insulin sensitivity, we performed insulin tolerance tests by measuring glucose concentrations after intraperitoneal insulin injection of 0.5 U/kg body weight. Glucose levels from all mice were significantly higher at all time points during the IPITT compared with control wild-type mice on an ND (unchanged in P2X7-KO-ND at 120 min, Fig. 3e). To investigate whether the impaired glucose tolerance and insulin secretion was due to a defect in beta cell survival together with beta cell function, we analysed beta cell mass from the four groups after 12 and 16 weeks of treatment. As reported previously [8], after 12 weeks of diet, islet beta cell mass was increased by high-fat feeding in the WT mice compared with those on a normal diet (1.6-fold increase, p < 0.01; Fig. 3f,g). In contrast, P2X7-KO mice had no such compensatory capacity in response to the HFD. There was no significant change in beta cell mass in the P2X7-KO mice fed the HFD compared with the P2X7-KO-ND mice. Moreover, beta cell mass was significantly decreased compared with the wild-type mice, independent of the diet (1.5-fold with ND and 1.5-fold with HFD, p < 0.0.01, Fig. 3f, g). This was confirmed after 16 weeks of diet. We have previously reported the tendency to beta cell apoptosis in mice after 12 weeks of HFD despite an increased beta cell mass at that time point [8]. Here, we analysed beta cell mass after 12 and 16 weeks of diet. In contrast to 12 weeks, there was no increase in beta cell mass in wild-type mice fed an HFD compared with ND-fed animals after 16 weeks. To investigate whether the changes in beta cell mass correlate with the increased rate of apoptosis, we analysed TUNEL-positive beta cells in pancreatic sections. After 16 weeks of diet, we observed a clear increase in beta cell apoptosis in the control HFD group. This was further increased in the P2X7-KO-HFD mice (1.5-fold raise in apoptosis in the WT-HFD and 11.2-fold in the P2X7-KO-HFD compared with ND controls, p < 0.01, Fig. 3h). As P2X7 regulates IL-1Ra secretion, we tested whether IL-1Ra levels are altered in P2X7-KO mice. The serum concentration of IL-1Ra was measured in WT and P2X7-KO mice during the 16 weeks of HFD feeding. In WT-ND mice, IL-1Ra levels were unchanged during the experiment. IL-1Ra levels were significantly lower in P2X7-KO-ND mice at 8, 12 and 16 weeks. Interestingly, after 4 weeks of diet, IL-1Ra increased 2.2-fold in the WT-HFD mice; these high levels were maintained at 8 weeks (1.9-fold compared with WT) and time-dependently decreased again after 12 and 16 weeks of diet (1.5-fold and 2.4-fold decrease from 8 weeks, respectively). After 16 weeks, IL-1Ra levels with HFD were lower than with the ND (2.6-fold decrease), which correlates with the changes in beta cell mass. P2X7-KO mice, which had beta cells unable to compensate via increasing beta cell mass, had no adaptive increase in IL-1Ra levels (Fig. 3i). We have also measured IL-1beta serum levels together with IL-1Ra in the mouse studies. Unfortunately, the levels were very low and mostly under the lower level of the ELISA kit. Positive IL-1beta readings were found for some but not all samples from the HFD-fed control mice at 12 and 16 weeks of diet, but none were found in the ND or P2X7-KO mice, making statistical data analysis not possible.
###end p 33
###begin p 34
###xml 3 4 3 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 142 143 142 143 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 311 312 311 312 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 342 343 342 343 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 424 425 424 425 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 565 566 565 566 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 596 597 596 597 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 657 658 657 658 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 876 877 876 877 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 962 963 962 963 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 986 987 986 987 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 1213 1214 1213 1214 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1244 1245 1244 1245 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1272 1273 1272 1273 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 1364 1365 1364 1365 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1426 1427 1426 1427 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 1540 1541 1540 1541 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1559 1560 1559 1560 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1617 1618 1617 1618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1919 1920 1919 1920 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 2365 2366 2361 2362 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 2377 2378 2373 2374 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 2492 2493 2488 2489 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 2504 2505 2500 2501 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 2505 2506 2501 2502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2542 2543 2538 2539 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 2543 2544 2539 2540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2563 2564 2559 2560 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 2581 2582 2577 2578 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 2582 2583 2578 2579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2614 2615 2610 2611 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 2615 2616 2611 2612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 15 19 <span type="species:ncbi:10090">mice</span>
###xml 369 373 <span type="species:ncbi:10090">mice</span>
###xml 407 411 <span type="species:ncbi:10090">mice</span>
###xml 623 627 <span type="species:ncbi:10090">mice</span>
###xml 753 757 <span type="species:ncbi:10090">mice</span>
###xml 980 984 <span type="species:ncbi:10090">mice</span>
###xml 1020 1024 <span type="species:ncbi:10090">mice</span>
###xml 1369 1373 <span type="species:ncbi:10090">mice</span>
###xml 1581 1585 <span type="species:ncbi:10090">mice</span>
###xml 1623 1627 <span type="species:ncbi:10090">mice</span>
###xml 2307 2311 <span type="species:ncbi:10090">mice</span>
###xml 2370 2374 <span type="species:ncbi:10090">mice</span>
###xml 2497 2501 <span type="species:ncbi:10090">mice</span>
###xml 2522 2526 <span type="species:ncbi:10090">mice</span>
###xml 2575 2579 <span type="species:ncbi:10090">mice</span>
P2X7-deficient mice have impaired glucose tolerance and beta cell mass and function and do not adapt IL-1Ra secretion during a high-fat diet. a Changes in body weight in response to the HFD were measured every week during the study and results are shown from WT-ND (black squares), WT-HFD (black triangles), P2X7-KO-ND (white squares) and P2X7-KO-HFD (white triangles) mice from three different studies (12 mice per group). b Blood glucose following i.p. injection of glucose at 1 g/kg body weight are shown from WT-ND (black squares), WT-HFD (black triangles), P2X7-KO-ND (white squares) and P2X7-KO-HFD (white triangles) mice after 12 weeks of treatment. c Serum insulin levels following i.p. injection of glucose at 1 g/kg body weight are shown from mice after 12 weeks of treatment; open bars show levels at 0 min, solid bars show levels at 30 min. The stimulatory index (d) denotes the ratio of stimulated and basal insulin levels in WT (black bars) and P2X7-KO (white bars) mice. e Blood glucose concentrations in mice undergoing an insulin tolerance test after 12 weeks of treatment. Insulin was injected i.p. at a concentration of 0.5 U/kg body weight; WT-ND (black squares), WT-HFD (black triangles), P2X7-KO-ND (white squares) and P2X7-KO-HFD (white triangles). f Immunostaining for insulin in green (magnification x125) shows disrupted islets in the P2X7-KO mice, which was confirmed by analysis of beta cell mass (g) in tissue sections spanning the width of the whole pancreas from (1) WT-ND and (2) WT-HFD (black bars), (3) P2X7-KO-ND and (4) P2X7-KO-HFD (white bars) mice after 12 and 16 weeks of diet (n = 4 mice for each group). Beta cell mass per pancreas was estimated as the product of the relative cross-sectional area of beta cells (determined by quantification of the cross-sectional area occupied by beta cells divided by the cross-sectional area of total tissue) and the weight of the pancreas. h Analysis of beta cell apoptosis by triple staining for TUNEL, insulin and DAPI (a fluorescent stain that binds strongly to DNA) was performed on the same pancreatic sections. Results are expressed as percentage of TUNEL-positive beta cells +/- SE normalised to control ND islets. The mean number of beta cells scored was 6,239 +/- 1,035 for each treatment condition from six individual mice per treatment (solid bars represent WT, open bars P2X7-KO mice). i Serum levels of IL-1Ra were measured after 4, 8, 12 and 16 weeks of diet (black bars represent WT, white bars P2X7-KO mice). ap < 0.05 between mice on ND and HFD; bp < 0.05 between P2X7-KO and WT mice; cp < 0.05 GSIS: 30 min vs 0 min; dp < 0.05 beta cell mass: 16 weeks vs 12 weeks
###end p 34
###begin p 35
###xml 24 25 24 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 0 99 0 96 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Isolated islets from P2X<sub>7</sub>-deficient mice display a defect in insulin, IL-1Ra and IL-1&#946; secretion</bold>
###xml 165 166 162 163 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 537 538 534 535 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 557 558 554 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 670 671 667 668 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 735 736 732 733 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 788 789 785 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 850 851 847 848 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1119 1120 1116 1117 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1201 1202 1198 1199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 1280 1281 1277 1278 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1459 1460 1453 1454 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1477 1478 1471 1472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 1482 1488 1476 1482 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;4</label>
###xml 1512 1513 1506 1507 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1568 1569 1562 1563 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1571 1572 1565 1566 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1652 1653 1646 1647 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1667 1668 1661 1662 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1784 1785 1778 1779 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 2125 2126 2117 2118 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 2342 2343 2334 2335 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 2354 2355 2346 2347 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 2447 2448 2439 2440 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 2576 2577 2568 2569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 2693 2694 2685 2686 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 2713 2714 2705 2706 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 2801 2802 2790 2791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 2832 2833 2821 2822 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 2833 2834 2822 2823 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2877 2878 2866 2867 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 2878 2879 2867 2868 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2921 2922 2910 2911 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 2922 2923 2911 2912 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 2942 2943 2931 2932 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 2960 2961 2949 2950 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 2961 2962 2950 2951 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1488 3028 1482 3017 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="36">Isolated islets from P2X<sub>7</sub>-deficient mice display a defect in insulin secretion. <bold>a</bold>, <bold>b</bold> For GSIS experiments, islets from all four treatment groups (WT-ND, WT-HFD, P2X<sub>7</sub>-KO-ND and P2X<sub>7</sub>-KO-HFD) were isolated after 12&#160;weeks of diet and pre-cultured for 24&#160;h on dishes coated with extracellular matrix. <bold>a</bold> Glucose-stimulated insulin secretion of islets. Basal (white bars) and stimulated (black bars) insulin secretion during successive 1&#160;h incubations at 2.8&#160;mmol/l (basal) and 16.7&#160;mmol/l (stimulated) glucose divided by the corresponding insulin content and expressed as means&#8201;&#177;&#8201;SE, normalised to control conditions at 11.1&#160;mmol/l glucose. <bold>b</bold> The stimulatory index denotes the ratio between stimulated and basal values of insulin secretion. The assay was performed in triplicate with samples from four individual mice (black bars represent WT, white bars P2X<sub>7</sub>-KO mice). <bold>c</bold> Chronic insulin secretion over 8&#160;h from islets isolated from ND-fed WT (black bars) and P2X<sub>7</sub>-KO (white bars) mice exposed to 11.1 or 33.3&#160;mmol/l glucose, or 11.1&#160;mmol/l glucose and 0.5&#160;mmol/l palmitate (NEFA). Values on <italic>x</italic>-axis shown glucose (mmol/l). Glucose and palmitate stimulated insulin secretion in the wild-type but not in the P2X<sub>7</sub>-deficient islets. <bold>d</bold> IL-1Ra and IL-1&#946; secretion from the same islets after 72&#160;h of treatment. Values on <italic>x</italic>-axis shown glucose (mmol/l). <sup>a</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 GSIS: stimulated vs basal glucose; <sup>b</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 between ND- and HFD-treated mice; <sup>c</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 between P2X<sub>7</sub>-KO and WT mice; <sup>d</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 treated (33.3&#160;mmol/l glucose or NEFA) vs untreated control</p>
###xml 1488 3028 1482 3017 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="36">Isolated islets from P2X<sub>7</sub>-deficient mice display a defect in insulin secretion. <bold>a</bold>, <bold>b</bold> For GSIS experiments, islets from all four treatment groups (WT-ND, WT-HFD, P2X<sub>7</sub>-KO-ND and P2X<sub>7</sub>-KO-HFD) were isolated after 12&#160;weeks of diet and pre-cultured for 24&#160;h on dishes coated with extracellular matrix. <bold>a</bold> Glucose-stimulated insulin secretion of islets. Basal (white bars) and stimulated (black bars) insulin secretion during successive 1&#160;h incubations at 2.8&#160;mmol/l (basal) and 16.7&#160;mmol/l (stimulated) glucose divided by the corresponding insulin content and expressed as means&#8201;&#177;&#8201;SE, normalised to control conditions at 11.1&#160;mmol/l glucose. <bold>b</bold> The stimulatory index denotes the ratio between stimulated and basal values of insulin secretion. The assay was performed in triplicate with samples from four individual mice (black bars represent WT, white bars P2X<sub>7</sub>-KO mice). <bold>c</bold> Chronic insulin secretion over 8&#160;h from islets isolated from ND-fed WT (black bars) and P2X<sub>7</sub>-KO (white bars) mice exposed to 11.1 or 33.3&#160;mmol/l glucose, or 11.1&#160;mmol/l glucose and 0.5&#160;mmol/l palmitate (NEFA). Values on <italic>x</italic>-axis shown glucose (mmol/l). Glucose and palmitate stimulated insulin secretion in the wild-type but not in the P2X<sub>7</sub>-deficient islets. <bold>d</bold> IL-1Ra and IL-1&#946; secretion from the same islets after 72&#160;h of treatment. Values on <italic>x</italic>-axis shown glucose (mmol/l). <sup>a</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 GSIS: stimulated vs basal glucose; <sup>b</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 between ND- and HFD-treated mice; <sup>c</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 between P2X<sub>7</sub>-KO and WT mice; <sup>d</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 treated (33.3&#160;mmol/l glucose or NEFA) vs untreated control</p></caption>
###xml 3028 3028 3017 3017 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="125_2009_1349_Fig4_HTML" id="MO4"/>
###xml 1482 3028 1476 3017 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig4"><label>Fig.&#160;4</label><caption><p textid="36">Isolated islets from P2X<sub>7</sub>-deficient mice display a defect in insulin secretion. <bold>a</bold>, <bold>b</bold> For GSIS experiments, islets from all four treatment groups (WT-ND, WT-HFD, P2X<sub>7</sub>-KO-ND and P2X<sub>7</sub>-KO-HFD) were isolated after 12&#160;weeks of diet and pre-cultured for 24&#160;h on dishes coated with extracellular matrix. <bold>a</bold> Glucose-stimulated insulin secretion of islets. Basal (white bars) and stimulated (black bars) insulin secretion during successive 1&#160;h incubations at 2.8&#160;mmol/l (basal) and 16.7&#160;mmol/l (stimulated) glucose divided by the corresponding insulin content and expressed as means&#8201;&#177;&#8201;SE, normalised to control conditions at 11.1&#160;mmol/l glucose. <bold>b</bold> The stimulatory index denotes the ratio between stimulated and basal values of insulin secretion. The assay was performed in triplicate with samples from four individual mice (black bars represent WT, white bars P2X<sub>7</sub>-KO mice). <bold>c</bold> Chronic insulin secretion over 8&#160;h from islets isolated from ND-fed WT (black bars) and P2X<sub>7</sub>-KO (white bars) mice exposed to 11.1 or 33.3&#160;mmol/l glucose, or 11.1&#160;mmol/l glucose and 0.5&#160;mmol/l palmitate (NEFA). Values on <italic>x</italic>-axis shown glucose (mmol/l). Glucose and palmitate stimulated insulin secretion in the wild-type but not in the P2X<sub>7</sub>-deficient islets. <bold>d</bold> IL-1Ra and IL-1&#946; secretion from the same islets after 72&#160;h of treatment. Values on <italic>x</italic>-axis shown glucose (mmol/l). <sup>a</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 GSIS: stimulated vs basal glucose; <sup>b</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 between ND- and HFD-treated mice; <sup>c</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 between P2X<sub>7</sub>-KO and WT mice; <sup>d</sup><italic>p</italic>&#8201;&lt;&#8201;0.05 treated (33.3&#160;mmol/l glucose or NEFA) vs untreated control</p></caption><graphic position="anchor" xlink:href="125_2009_1349_Fig4_HTML" id="MO4"/></fig>
###xml 36 40 <span type="species:ncbi:10090">mice</span>
###xml 177 181 <span type="species:ncbi:10090">mice</span>
###xml 481 485 <span type="species:ncbi:10090">mice</span>
###xml 546 550 <span type="species:ncbi:10090">mice</span>
###xml 678 682 <span type="species:ncbi:10090">mice</span>
###xml 707 711 <span type="species:ncbi:10090">mice</span>
###xml 744 748 <span type="species:ncbi:10090">mice</span>
###xml 777 781 <span type="species:ncbi:10090">mice</span>
###xml 855 859 <span type="species:ncbi:10090">mice</span>
###xml 1124 1128 <span type="species:ncbi:10090">mice</span>
###xml 1285 1289 <span type="species:ncbi:10090">mice</span>
###xml 1524 1528 <span type="species:ncbi:10090">mice</span>
###xml 2297 2301 <span type="species:ncbi:10090">mice</span>
###xml 2347 2351 <span type="species:ncbi:10090">mice</span>
###xml 2465 2469 <span type="species:ncbi:10090">mice</span>
###xml 2915 2919 <span type="species:ncbi:10090">mice</span>
###xml 2954 2958 <span type="species:ncbi:10090">mice</span>
Isolated islets from P2X7-deficient mice display a defect in insulin, IL-1Ra and IL-1beta secretion As we observed impaired glucose tolerance and survival in the P2X7-deficient mice in vivo, we investigated whether impaired beta cell insulin secretion could explain this effect. Islets were isolated from all four treatment groups and insulin secretion into the culture medium was measured. Acute glucose-stimulated insulin secretion was abolished in islets derived from wild-type mice fed a high-fat diet and was further impaired in P2X7-KO-HFD mice (Fig. 4a). The stimulatory index (the ratio of stimulated to basal insulin secretion) was decreased 1.2-fold in the P2X7-KO-ND mice, 2.4-fold in the WT-HFD mice and 3.4-fold in the P2X7-KO-HFD mice compared with WT-ND control mice (Fig. 4b). These data confirm the impaired beta cell function in P2X7-KO mice from our in vivo studies on the level of isolated islets. We then incubated the islets for 8 h at 33.3 mmol/l glucose or 0.5 mmol/l palmitate. As expected, glucose and palmitate increased insulin secretion in the wild-type islets. In contrast, islets from P2X7-KO mice did not increase insulin secretion in response to the stimulation (Fig. 4c). These data confirm the lack of stimulation of insulin secretion in the P2X7-KO mice. Under the same culture conditions, 72 h incubation of islets with 0.5 mmol/l palmitate increased IL-1Ra as well as IL-1beta secretion from the wild-type but not the P2X7-KO islets (Fig. 4d). Fig. 4Isolated islets from P2X7-deficient mice display a defect in insulin secretion. a, b For GSIS experiments, islets from all four treatment groups (WT-ND, WT-HFD, P2X7-KO-ND and P2X7-KO-HFD) were isolated after 12 weeks of diet and pre-cultured for 24 h on dishes coated with extracellular matrix. a Glucose-stimulated insulin secretion of islets. Basal (white bars) and stimulated (black bars) insulin secretion during successive 1 h incubations at 2.8 mmol/l (basal) and 16.7 mmol/l (stimulated) glucose divided by the corresponding insulin content and expressed as means +/- SE, normalised to control conditions at 11.1 mmol/l glucose. b The stimulatory index denotes the ratio between stimulated and basal values of insulin secretion. The assay was performed in triplicate with samples from four individual mice (black bars represent WT, white bars P2X7-KO mice). c Chronic insulin secretion over 8 h from islets isolated from ND-fed WT (black bars) and P2X7-KO (white bars) mice exposed to 11.1 or 33.3 mmol/l glucose, or 11.1 mmol/l glucose and 0.5 mmol/l palmitate (NEFA). Values on x-axis shown glucose (mmol/l). Glucose and palmitate stimulated insulin secretion in the wild-type but not in the P2X7-deficient islets. d IL-1Ra and IL-1beta secretion from the same islets after 72 h of treatment. Values on x-axis shown glucose (mmol/l). ap < 0.05 GSIS: stimulated vs basal glucose; bp < 0.05 between ND- and HFD-treated mice; cp < 0.05 between P2X7-KO and WT mice; dp < 0.05 treated (33.3 mmol/l glucose or NEFA) vs untreated control
###end p 35
###begin p 36
###xml 24 25 24 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 80 81 80 81 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 83 84 83 84 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 164 165 164 165 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 179 180 179 180 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 296 297 296 297 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 637 638 635 636 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 854 855 852 853 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 866 867 864 865 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 959 960 957 958 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1088 1089 1086 1087 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 1205 1206 1203 1204 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1225 1226 1223 1224 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 1313 1314 1308 1309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">x</italic>
###xml 1344 1345 1339 1340 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1345 1346 1340 1341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1389 1390 1384 1385 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1390 1391 1385 1386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1433 1434 1428 1429 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 1434 1435 1429 1430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1454 1455 1449 1450 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1472 1473 1467 1468 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 1473 1474 1468 1469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 36 40 <span type="species:ncbi:10090">mice</span>
###xml 809 813 <span type="species:ncbi:10090">mice</span>
###xml 859 863 <span type="species:ncbi:10090">mice</span>
###xml 977 981 <span type="species:ncbi:10090">mice</span>
###xml 1427 1431 <span type="species:ncbi:10090">mice</span>
###xml 1466 1470 <span type="species:ncbi:10090">mice</span>
Isolated islets from P2X7-deficient mice display a defect in insulin secretion. a, b For GSIS experiments, islets from all four treatment groups (WT-ND, WT-HFD, P2X7-KO-ND and P2X7-KO-HFD) were isolated after 12 weeks of diet and pre-cultured for 24 h on dishes coated with extracellular matrix. a Glucose-stimulated insulin secretion of islets. Basal (white bars) and stimulated (black bars) insulin secretion during successive 1 h incubations at 2.8 mmol/l (basal) and 16.7 mmol/l (stimulated) glucose divided by the corresponding insulin content and expressed as means +/- SE, normalised to control conditions at 11.1 mmol/l glucose. b The stimulatory index denotes the ratio between stimulated and basal values of insulin secretion. The assay was performed in triplicate with samples from four individual mice (black bars represent WT, white bars P2X7-KO mice). c Chronic insulin secretion over 8 h from islets isolated from ND-fed WT (black bars) and P2X7-KO (white bars) mice exposed to 11.1 or 33.3 mmol/l glucose, or 11.1 mmol/l glucose and 0.5 mmol/l palmitate (NEFA). Values on x-axis shown glucose (mmol/l). Glucose and palmitate stimulated insulin secretion in the wild-type but not in the P2X7-deficient islets. d IL-1Ra and IL-1beta secretion from the same islets after 72 h of treatment. Values on x-axis shown glucose (mmol/l). ap < 0.05 GSIS: stimulated vs basal glucose; bp < 0.05 between ND- and HFD-treated mice; cp < 0.05 between P2X7-KO and WT mice; dp < 0.05 treated (33.3 mmol/l glucose or NEFA) vs untreated control
###end p 36
###begin title 37
Discussion
###end title 37
###begin p 38
###xml 32 33 32 33 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 160 161 160 161 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 340 341 340 341 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 446 447 446 447 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 653 654 653 654 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1279 1281 1279 1281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 1412 1414 1412 1414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 1603 1604 1603 1604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 1851 1852 1851 1852 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 2258 2259 2258 2259 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 2319 2321 2319 2321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 49 54 <span type="species:ncbi:9606">human</span>
###xml 142 147 <span type="species:ncbi:9606">human</span>
###xml 241 249 <span type="species:ncbi:9606">patients</span>
###xml 451 455 <span type="species:ncbi:10090">mice</span>
###xml 463 467 <span type="species:ncbi:10090">mice</span>
###xml 658 662 <span type="species:ncbi:10090">mice</span>
###xml 1361 1365 <span type="species:ncbi:10090">mice</span>
###xml 1856 1860 <span type="species:ncbi:10090">mice</span>
###xml 2289 2294 <span type="species:ncbi:10090">mouse</span>
The present study shows that P2X7 is produced in human islets in the beta cell and is regulated during the progression of type 2 diabetes. In human obesity, P2X7 is produced in large amounts, but is downregulated in pancreases obtained from patients with type 2 diabetes, in lean as well as in obese individuals. These data suggest that P2X7 plays an important role in beta cell compensation. This is confirmed in our subsequent studies using P2X7-KO mice. These mice show impaired glucose tolerance and glucose-stimulated insulin secretion together with an increased number of apoptotic beta cells, which leads to a decrease in beta cell mass. When P2X7-KO mice were challenged with a diet enriched with fat and sucrose, they became severely glucose intolerant and were completely unable to upregulate insulin secretion in response to glucose during an IPGTT in vivo or a GSIS assay in vitro. Although they had increased basal insulin levels, which indicate an attempt to adapt for the higher insulin demand, they were unable to compensate by increasing beta cell mass during the diet. Beta cell mass adaptation is an important mechanism to maintain normoglycaemia in obese insulin-resistant individuals, in whom beta cell mass is almost doubled compared with lean individuals [31]. Similar increases in beta cell mass in diet-induced obesity were measured in mice using a diet enriched with fat in a previous [32] or the present study. Interestingly, the high-fat/high-sucrose 'Surwit diet' induces an early reduction in beta cell proliferation at a time point when beta cell mass is still increased [8], indicating a development towards fewer cells. This tendency is substantiated in the present study, where we show a decrease in beta cell mass with time together with an induction of beta cell apoptosis after 16 weeks of diet. In comparison, P2X7-KO mice show a higher apoptosis rate under the ND as well as under the HFD. The increase in basal insulin levels in response to the diet together with a defect in the compensation of beta cell mass indicates that, despite the lower beta cell mass, high amounts of insulin can be secreted. However, the functional failure is apparent in the abolished response to glucose stimulation. A complete loss of P2X7 was also observed in the NOD mouse with manifest diabetes [33].
###end p 38
###begin p 39
###xml 316 318 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 324 325 324 325 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 492 493 492 493 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 339 342 <span type="species:ncbi:10116">rat</span>
###xml 392 397 <span type="species:ncbi:9606">human</span>
Little is known about the purinergic receptor family in the beta cell and the effects on insulin release are controversial. A low concentration of ATP stimulates insulin secretion via the metabotropic purinergic receptor subtype P2Y rather than via P2X receptors (the ionotropic selective cation channel receptors) [34]. P2X7 was found in rat alpha but not beta cells [33], its production in human islets has not been studied before. Here, we show clearly the production and regulation of P2X7 in the beta cell.
###end p 39
###begin p 40
###xml 63 64 63 64 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 136 137 136 137 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 217 218 217 218 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 302 303 302 303 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 428 429 428 429 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 558 559 558 559 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
Fibroblasts from donors with type 2 diabetes have increased P2X7-mediated responses compared with non-diabetic donors, but levels of P2X7 were unchanged [24]. In contrast, we report here a decrease in the level of P2X7 in beta cells in type 2 diabetes. Consistent with the results from fibroblasts, P2X7 activation was enhanced in isolated islets by a diabetic milieu (high glucose and palmitic acid), an effect prevented by P2X7 inhibition. High glucose induces caspase 3 activation in beta cells as well as in fibroblasts. It is possible that beta cell P2X7 receptors are activated and produced in high numbers at a time when IL-1Ra is highly secreted (e.g. in obesity) and when diabetes develops, levels are lowered in specific cells.
###end p 40
###begin p 41
###xml 53 54 53 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 115 116 115 116 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 157 158 157 158 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 328 329 328 329 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
Our in vitro studies on isolated islets show that P2X7 is directly involved in insulin secretion. Activation of P2X7 by BzATP (which specifically targets P2X7 receptors [27, 35, 36]) or acute stimulation of insulin secretion by glucose or palmitic acid for 1 h resulted in insulin release that was partially inhibited by two P2X7 inhibitors.
###end p 41
###begin p 42
###xml 137 138 137 138 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
Although secretory pathways of insulin and IL-1Ra are distinct, one possible common step could be the calcium exchange; activation of P2X7 increases intracellular calcium levels by calcium influx from the extracellular space. This leads to activation of the leaderless IL-1Ra-releasing pathway through pore formation. Increased intracellular calcium levels would also be a trigger for exocytosis of insulin-containing secretory granules.
###end p 42
###begin p 43
###xml 34 35 34 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 52 54 52 54 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">37</xref>
###xml 206 207 206 207 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 253 254 253 254 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 305 306 305 306 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 385 386 385 386 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
High glucose can also activate P2X7 in fibroblasts [37]. In parallel, BzATP, glucose and palmitic acid induced short-term secretion of IL-1Ra, which was also inhibited by KN-62. Apyrase, a less specific P2X7 inhibitor that affects the ligands of all P2X7 receptors, showed similarities to the specific P2X7 inhibitor KN-62 in blocking the effect of BzATP on islets, suggesting that P2X7 is mainly activated by glucose and palmitic acid in islets.
###end p 43
###begin p 44
###xml 205 206 205 206 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">38</xref>
###xml 305 306 305 306 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 599 600 593 594 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 613 615 607 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 715 716 706 707 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 1001 1002 986 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 1004 1005 989 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
Intracellular IL-1Ra has no signal peptide. A possible mechanism for release of intracellular IL-1Ra from the cells to bind to IL-1R1 is through vesicle shedding, which occurs through activation of the P2X7 by ATP [38]. Our data indicate that IL-1Ra secretion is an ATP-dependent process that requires P2X7 activation. This may be how intracellular IL-1Ra, as well as IL-1beta, is released from beta cells. Similar results are obtained from macrophages and endothelial cells, demonstrating that intracellular IL-1Ra and IL-1beta are secreted by an extracellular ATP-dependent mechanism involving P2X7 activation [14]. We hypothesised that the balance of IL-1beta and IL-1Ra is crucial for the onset of diabetes. P2X7 receptors have a dual role in this system: they mediate the release of both pro-inflammatory IL-1beta and anti-inflammatory IL-1Ra. From in vitro experiments we know that an excess of 10- to 1,000-fold IL-1Ra is needed to inhibit the IL-1beta effects, dependent on the exposure time [4, 9]. Betaeta cell dysfunction and increased apoptosis may occur rapidly when IL-1Ra levels are decreased.
###end p 44
###begin p 45
###xml 36 37 36 37 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">39</xref>
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">42</xref>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">43</xref>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">44</xref>
###xml 832 833 829 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 975 976 972 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 341 345 <span type="species:ncbi:10090">mice</span>
###xml 806 810 <span type="species:ncbi:10090">mice</span>
###xml 1220 1226 <span type="species:ncbi:9606">humans</span>
Corresponding with the levels of P2X7, increased IL-1Ra serum levels correlate with obesity and insulin resistance [39-42], whereas IL-1Ra is decreased in type 2 diabetes [43]. Recent results from the Whitehall II study show that IL-1Ra levels are increased before the onset of type 2 diabetes [44], which is consistent with our findings in mice fed with an HFD. The increase in IL-1Ra could be an attempt by the body to counteract the deleterious effects of IL-1beta and to preserve beta cell survival, insulin secretion and insulin sensitivity. In contrast, it has been speculated that increased IL-1Ra could have an additional metabolic effect that leads to insulin resistance. This is not supported by our results, as daily IL-1Ra injections over 12 weeks did not impair insulin sensitivity in C57Bl/6 mice in a previous study [8], and increased IL-1Ra levels did not lead to changes in insulin sensitivity in the present study. As shown by the bell-shaped curve in Fig. 3i, decreased IL-1Ra levels occurred together with the increase in beta cell apoptosis and the development of diabetes in our study. It will now be important to determine whether long-standing type 2 diabetes leads to decreased IL-1Ra levels in humans in a follow-up study.
###end p 45
###begin title 46
Electronic Supplementary Material
###end title 46
###begin p 47
Below is the link to the electronic supplementary material.
###end p 47
###begin p 48
(PDF 75.5 kb)
###end p 48
###begin p 49
###xml 75 76 75 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
Clinical data from the autopsy study, results from which are shown in Fig. 1d (PDF 22.3 kb)
###end p 49
###begin title 50
Acknowledgements
###end title 50
###begin p 51
###xml 438 443 <span type="species:ncbi:9606">Human</span>
###xml 1082 1087 <span type="species:ncbi:9606">human</span>
This work was supported by the American Diabetes Association (Junior Faculty Grant 706JF41), the German Research Foundation (DFG, Emmy Noether Program, MA 4172/1-1) and the European Foundation for the Study of Diabetes (EFSD)/Merck Sharp & Dohme. R. Glas is a recipient of the German Research Foundation Fellowship award (Schr 1166/1-1), N. S. Sauter and F. T. Schulthess are recipients of the Swiss National Foundation Fellowship award. Human islets were provided through the Islet Cell Resource Consortium, administered by the Administrative Bioinformatics Coordinating Center (ABCC) and supported by the National Center for Research Resources (NCRR), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Juvenile Diabetes Research Foundation (JDRF). We thank J. Bergemann (Uni Bremen), H. Gerber, M. Kennedy and L. N. Le (UCLA) for excellent technical assistance, C. Lyon (UCLA) for help with the luminex assays and P. U. Heitz, P. Komminoth, P. Saremaslani (University Hospital Zurich) and the National Disease Research Interchange for providing human pancreatic sections.
###end p 51
###begin p 52
###xml 0 19 0 19 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Duality of interest</bold>
Duality of interest The authors declare that there is no duality of interest associated with this manuscript.
###end p 52
###begin p 53
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 53
###begin title 54
References
###end title 54
###begin article-title 55
Global and societal implications of the diabetes epidemic
###end article-title 55
###begin article-title 56
Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study
###end article-title 56
###begin article-title 57
Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications
###end article-title 57
###begin article-title 58
###xml 90 95 <span type="species:ncbi:9606">human</span>
Glucose-induced beta-cell production of interleukin-1beta contributes to glucotoxicity in human pancreatic islets
###end article-title 58
###begin article-title 59
The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1
###end article-title 59
###begin article-title 60
A urine inhibitor of interleukin 1 activity that blocks ligand binding
###end article-title 60
###begin article-title 61
A urine inhibitor of interleukin 1 activity affects both interleukin 1 alpha and 1 beta but not tumor necrosis factor alpha
###end article-title 61
###begin article-title 62
The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia
###end article-title 62
###begin article-title 63
An interleukin-1 receptor antagonist protein protects insulin-producing beta cells against suppressive effects of interleukin-1 beta
###end article-title 63
###begin article-title 64
###xml 77 82 <span type="species:ncbi:9606">human</span>
Adenoviral gene transfer of the interleukin-1 receptor antagonist protein to human islets prevents IL-1beta-induced beta-cell impairment and activation of islet cell apoptosis in vitro
###end article-title 64
###begin article-title 65
###xml 87 91 <span type="species:ncbi:10090">mice</span>
Interleukin-1 receptor antagonist prevents low dose streptozotocin induced diabetes in mice
###end article-title 65
###begin article-title 66
###xml 75 80 <span type="species:ncbi:10090">mouse</span>
Protection from experimental autoimmune diabetes in the non-obese diabetic mouse with soluble interleukin-1 receptor
###end article-title 66
###begin article-title 67
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
###end article-title 67
###begin article-title 68
Secretion of intracellular IL-1 receptor antagonist (type 1) is dependent on P2X7 receptor activation
###end article-title 68
###begin article-title 69
###xml 84 89 <span type="species:ncbi:9606">human</span>
The cytokine IL-1beta transiently enhances P2X7 receptor expression and function in human astrocytes
###end article-title 69
###begin article-title 70
ATP is released by monocytes stimulated with pathogen-sensing receptor ligands and induces IL-1beta and IL-18 secretion in an autocrine way
###end article-title 70
###begin article-title 71
The P2X7 receptor: a key player in IL-1 processing and release
###end article-title 71
###begin article-title 72
Astrocyte-derived ATP induces vesicle shedding and IL-1 beta release from microglia
###end article-title 72
###begin article-title 73
###xml 42 46 <span type="species:ncbi:10090">mice</span>
Diet-induced type II diabetes in C57BL/6J mice
###end article-title 73
###begin article-title 74
Distinct effects of saturated and monounsaturated fatty acids on beta-cell turnover and function
###end article-title 74
###begin article-title 75
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human islet transplantation: lessons from 13 autologous and 13 allogeneic transplantations
###end article-title 75
###begin article-title 76
CXCL10 impairs beta cell function and viability in diabetes through TLR4 signaling
###end article-title 76
###begin article-title 77
###xml 108 113 <span type="species:ncbi:9606">human</span>
Low concentration of interleukin-1beta induces FLICE-inhibitory protein-mediated beta-cell proliferation in human pancreatic islets
###end article-title 77
###begin article-title 78
###xml 26 31 <span type="species:ncbi:9606">human</span>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Enhanced P2X7 activity in human fibroblasts from diabetic patients: a possible pathogenetic mechanism for vascular damage in diabetes
###end article-title 78
###begin article-title 79
###xml 35 40 <span type="species:ncbi:9606">human</span>
Measurement of apoptosis of intact human islets by confocal optical sectioning and stereologic analysis of YO-PRO(R)-1-stained islets
###end article-title 79
###begin article-title 80
###xml 71 76 <span type="species:ncbi:9606">human</span>
Partial agonists and antagonists reveal a second permeability state of human lymphocyte P2Z/P2X7 channel
###end article-title 80
###begin article-title 81
The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7)
###end article-title 81
###begin article-title 82
###xml 93 98 <span type="species:ncbi:9606">human</span>
Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets
###end article-title 82
###begin article-title 83
###xml 127 132 <span type="species:ncbi:9606">human</span>
Is there a role for locally produced interleukin-1 in the deleterious effects of high glucose or the type 2 diabetes milieu to human pancreatic islets?
###end article-title 83
###begin article-title 84
###xml 104 108 <span type="species:ncbi:10090">mice</span>
Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6 J and A/J mice
###end article-title 84
###begin article-title 85
###xml 55 61 <span type="species:ncbi:9606">humans</span>
Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes
###end article-title 85
###begin article-title 86
###xml 31 35 <span type="species:ncbi:10090">mice</span>
Dietary-fat-induced obesity in mice results in beta cell hyperplasia but not increased insulin release: evidence for specificity of impaired beta cell adaptation
###end article-title 86
###begin article-title 87
###xml 77 81 <span type="species:ncbi:10116">rats</span>
P2X and P2Y purinoceptor expression in pancreas from streptozotocin-diabetic rats
###end article-title 87
###begin article-title 88
###xml 111 114 <span type="species:ncbi:10116">rat</span>
Effect of purinergic agonists and antagonists on insulin secretion from INS-1 cells (insulinoma cell line) and rat pancreatic islets
###end article-title 88
###begin article-title 89
Activation of P2X7 receptors causes isoform-specific translocation of protein kinase C in osteoclasts
###end article-title 89
###begin article-title 90
###xml 82 87 <span type="species:ncbi:9606">human</span>
P2X7 receptor modulation of beta-amyloid- and LPS-induced cytokine secretion from human macrophages and microglia
###end article-title 90
###begin article-title 91
###xml 58 63 <span type="species:ncbi:9606">human</span>
High glucose modulates P2X7 receptor-mediated function in human primary fibroblasts
###end article-title 91
###begin article-title 92
Rapid secretion of interleukin-1beta by microvesicle shedding
###end article-title 92
###begin article-title 93
Diverse effect of inflammatory markers on insulin resistance and insulin-resistance syndrome in the elderly
###end article-title 93
###begin article-title 94
###xml 55 60 <span type="species:ncbi:9606">human</span>
IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin?
###end article-title 94
###begin article-title 95
Changes in inflammatory cytokines are related to impaired glucose tolerance in offspring of type 2 diabetic subjects
###end article-title 95
###begin article-title 96
Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome
###end article-title 96
###begin article-title 97
###xml 90 98 <span type="species:ncbi:9606">patients</span>
Interleukin-1 receptor antagonist genotype is associated with coronary atherosclerosis in patients with type 2 diabetes
###end article-title 97
###begin article-title 98
Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist (IL-1Ra) precede the onset of type 2 diabetes (Whitehall II Study)
###end article-title 98
###begin title 99
Abbreviations
###end title 99
###begin p 100
Benzoyl ATP
###end p 100
###begin p 101
Glucose-stimulated insulin secretion
###end p 101
###begin p 102
High-fat/high-sucrose diet
###end p 102
###begin p 103
Interleukin-1
###end p 103
###begin p 104
Interleukin-1 receptor antagonist
###end p 104
###begin p 105
Intraperitoneal glucose tolerance test
###end p 105
###begin p 106
Intraperitoneal insulin tolerance test
###end p 106
###begin p 107
Normal diet
###end p 107
###begin p 108
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P2x7</italic>
P2x7 knockout
###end p 108
###begin p 109
###xml 3 4 3 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7</sub>
P2X7 receptor
###end p 109
###begin p 110
Wild-type
###end p 110
###begin p 111
###xml 0 33 0 33 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Electronic supplementary material</bold>
Electronic supplementary material
###end p 111
###begin p 112
The online version of this article (doi:10.1007/s00125-009-1349-0) contains supplementary material, which is available to authorised users.
###end p 112

